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The goals of this work are to (a) compare the blood-brain barrier (BBB) 
modulatory activities of cyclic cHAVc3 (cyclo(1,6)Ac-CSHAVC-NH2) and linear HAV4 
(Ac-SHAVAS-NH2) peptides, (b) compare the rat plasma stability of HAV4 and 
cHAVc3, and (c) probe the mechanism of binding of HAV peptides (i.e., HAV6, 
cHAVc3) and ADT peptides (i.e., ADTc5, ADTc7, ADTc9) to the EC1 domain of E-
cadherin. The cyclic and linear HAV and ADT peptides were derived from the EC1 
domain of human E-cadherin. Cyclic cHAVc3 was more effective than linear HAV4 in 
modulating MDCK cell monolayers and in improving in vivo brain delivery of Gd-
DTPA upon i.v. administration in Balb/c mice. In vivo, the duration of the BBB 
modulation was longer for cyclic cHAVc3 (2–4 h) than for linear HAV4 (<1 h). Both 
HAV4 and cHAVc3 peptides also enhanced the in vivo brain delivery of IRdye800cw-
PEG (25 kDa) as detected by near IR imaging. Cyclic cHAVc3 (t1/2 = 12.95 h) has better 
plasma stability compared to linear HAV4 (t1/2 = 2.4 h). Using 2D 1H,-15N-HSQC NMR, 
molecular dynamics, and molecular docking simulations, cyclic cHAVc3 peptide was 
shown to bind at residues Y36, S37, I38, I53, F77, S78, H79, and I94 on the EC1 domain 
of human E-cadherin. Using chemical shift perturbations of several residues, the 
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dissociation constants (Kd values) of cHAVc3 peptide to EC1 were estimated to be 
between 0.5 × 10-5 and 7.0 × 10-5 M. In summary, cyclic cHAVc3 peptide has better 
plasma stability and in vitro and in vivo activities to modulate BBB than linear HAV4 
peptide. The proposed mechanism of modulatory activity of HAV and ADT peptides is 
due to binding to the EC1 domain of E-cadherin. Using NMR and molecular docking 
techniques, HAV and ADT peptides were found to bind to the EC1 domain and the 
binding site of HAV peptides in EC1 was different from ADT peptides. The ADT and 
HAV peptides bind to the EC1 domain with different affinities. ADTc5 and ADTc7 
peptides showed lower dissociation constants (Kd ~  10 µM) than ADTc9 peptide that 
showed a higher Kd values (Kd ~ 190 µM). HAV6 peptide showed similar binding site 
for cHAVc3 peptide on the EC1 domain with higher Kd values (Kd ~ 190 µM) in 
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1.1 The Biological Barriers to Delivery of Drugs to the Brain 
1.1.1 The Blood Brain Barrier (BBB) 
Many brain diseases are difficult to treat because it is challenging to deliver 
drugs to the brain. This is due to the presence of the blood–brain barrier (BBB), which 
restricts transport of drugs into the brain. The BBB in the human brain consists of 
microvessel endothelium with a surface area of approximately 20 m2 [1]. The BBB acts 
as a physical, enzymatic, and transporter barrier to allow nutrients and prevent 
unwanted molecules from entering the brain [2-4]. Therefore, it is difficult to design and 
develop drugs that can readily enter the brain for pharmacological effects. To improve 
drug delivery to the brain, it is necessary to understand how drugs can cross the BBB. 
Drugs can pass through the BBB via the transcellular pathway by partitioning into the 
cell membranes of the BBB endothelial cells; the drugs then enter the cytoplasmic 
domain and cross into the brain [3, 5]. This route is limited by the presence of efflux 
pumps and/or poor physicochemical properties of the drugs. Alternatively, drugs can 
percolate through the paracellular pathways of the BBB; unfortunately, the paracellular 
(intercellular) pathways have tight junctions that limit the ability of molecules to cross 
the paracellular pathways [3, 5].  The blood–brain barrier presents physical, chemical 




 3  
 
Figure 1. Drug molecules can enter the brain via paracellular and transcellular 
pathways. Paracellular (intercellular junction) pathway can be modulated by using 
synthetic intercellular junctions peptides such occludin, claudin and cadherin peptides. 
Transcellular passive diffusion can be modified or inhibited by efflux pumps (i.e., P-gp). 
Prodrugs have been used to improve the physicochemical properties of drugs for 
favorable passive diffusion through the BBB.  
 
1.1.2 Intercellular Junction in Biological Barriers  
1.1.2.1 Tight Junctions 
The junctional complex in paracellular pathway of epithelial and endothelial 
cells responsible for the cell-cell adhesion function, maintain tissues integrity and 
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polarity. This complex is comprised of and aligned from apical to basolateral- tight 
junction (TJ), adherens junction, and desmosomes. The TJ are mediated by protein–
protein interactions, including occludins, claudins, junctional adhesion molecules 
(JAM), and zonula occludins-1, -2 and -3. The TJ region, in paracellular pathway, works 
as a gate that controls the passage of molecules such as ions and maintains polarization 
of epithelial and endothelial cells by preventing the passive diffusion of lipids and 
proteins. Occludin and claudin are integral membrane proteins of the TJ working as a 
backbone for the TJ.  The third integral membrane protein JAM suggested to be more 
important as a barrier regulator for T-cells during immune and inflammatory responses 
in epithelial and endothelial tissues [6, 7]. 
1.1.2.1.1 Tight Junction Structure  
Occludin structure, a 62 kDa integral protein, showed two extracellular loops, 
four transmembrane domains with long C- and short N- termini intracellular domains 
[6]. Although occludin is known to be involved in the formation of TJ strands, some 
cells such as endothelial and non-neural tissues, can form tight-junction strands in gene 
knock out occludin that makes occludin function still unclear [8]. The claudin family 
consist of 24 members, 20-27 kDa, are involved in formation of TJ strands. Claudin 
structure as in occludin has two extracellular loops, four transmembrane domains and 
intracellular short C- and long N-termini. Claudin integral membrane proteins express 
more than two claudin species for TJ tightness. Claudin expression in different cells 
may vary based on claudin species and then their intercellular junction selectivity for 
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ions and their electrical resistance can vary. For example, in kidney almost all claudins 
were found and the transepithelial electrical resistance (TEER) values of nephron are 
low in proximal segments but in collecting duct of kidney TEER values are high that 
suggest different claudins can vary in their tightness. Moreover, claudins expression 
can be specific in some tissues such as claudin-5 is expressed specifically in endothelial 
cells of the blood vessels [8, 9]. JAM structure, 43 kDa protein belong to Ca2+ 
independent immunoglobulin family (IgG), has a single extracellular region consisting 
of two IgG domains linked by a disulfide bond (one domain form homophilic adhesion 
for adjacent cells), a one transmembrane domain and intracellular short C-terminus. 
1.1.2.2 Adherens Junctions  
Adherens junctions that are below the tight junctions are mediated by cadherins 
and nectins. Desmosomes are beneath the adherens junctions and connected by 
desmocollins and desmogleins. Classical cadherin proteins are Ca2+ dependent 
transmembrane glycoproteins that dimerize and cluster to mediate the cell-cell 
adhesion located in adhesion junctions. Cadherins are expressed specifically in different 
tissues such as epithelial (E-cadherin), neural (N-cadherin), placental (P-cadherin) and 
vascular endothelial (VE-cadherin) tissues [10]. In addition to cell adhesion function, 
cadherins are involved in other biological functions such as signaling in tissues, cell 
morphogenesis, migration, and cytoskeletal organization. For example, signaling can be 
explained by the ability of cadherins (via adhesion property) to bring membranes of 
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opposite cells in close to each other allowing induction of juxtacrine signaling and by 
maintaining the cells polarization [11].    
1.1.2.2.1 Adherens Junctions Structure  
Cadherins structure is composed of five extracellular domains (EC1–EC5) that 
mediate the adhesion function with homophilic interaction, a single transmembrane 
and intracellular conserved region that link cadherins to cytoplasmic proteins. For 
example, N- and E-cadherin intracellular region links to β-catenin and the latter links to 
α-catenin and then to actin cytoskeleton network to strength the adhesion of cadherins 
protein. Other catenins include p-120 catenin that is claimed to be responsible for lateral 
clustering of cis-dimer [10, 11].  
1.1.2.2.2 Mechanism Action of Cadherin in the Formation and Maintaining the 
Integrity of the BBB 
Different mechanisms have been proposed for homophilic cadherins interaction 
in extracellular domains (EC). For instance, zipper model for N-cadherin interaction 
suggests that N-terminus cis-dimer from one cell interact with N-terminus cis-dimer of 
opposing cell in a trans-interaction manner (i.e. EC1 domain from cis-dimer to EC1 
domain from opposite cis-dimer) [12]. The monomeric E-cadherin of NMR experiments 
showed a similar cadherin interaction mechanism to the N-cadherin. The C-cadherin 
interaction can be trans-interaction but the EC1 from one cis-dimer of one cell interacts 
with EC2 domain cis-dimer from the opposite cell. Moreover, the C-cadherin show 
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trans-interaction involves more than one EC domains such as EC1 from one cell (A) to 
EC3 from opposite cell (B), EC2 (A) to EC2 (B), and EC3 (A) to EC1 (B) of cis-dimers (A 
and B) of the opposite cells [12, 13].  
1.1.2.3 Desmosomal Cadherins 
Desmosomal cadherins, similar to classical cadherins, have five extracellular 
domains that mediate the adhesion function with homophilic or heterophilic 
interactions. The desomosomal cadherins have two Ca2+ dependent subfamilies: 
desmocollin (DSC) and desmoglein (DSG) proteins. The adhesion mechanism for 
desmosome could be by trans-interaction of the adhesive surface of EC1 domains or N-
terminal hydrophobic pocket for conserved residue Trp2 [14]. For adhesion function of 
desmosomes, at least DSC, DSG, and plakoglobin components are required. DSC and 
DSG showed basic extracellular domains of the classical cadherin. Both DSC and DSG 
peptides are required to block the desmosome adhesion, in contrast to E-cadherin as 
one E-cadherin peptide can block adhesion of E-cadherin. The desmosome plaques are 
associated with cytoskeleton intermediate filaments (IFs). The link between the 
cytoplasmic part of the desmosomes and IFs is complex with high-organized protein 
network. Based on tissues type there is specific IF system, for example, in epithelial 
tissue desmosomal cytoplasmic plaque bind to cytokeratin filaments while in cardiac 
tissues desmosomal cytoplasmic plaque bind to desmin filament. This suggests the 
cytoplasmic domain of desmosome participate in junctional formation [14, 15].  
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1.2 Using Synthetic Intercellular Junction Peptides to Enhance Drug Delivery via the 
Biological Barriers 
1.2.1 The Disruption of Intercellular Junctions in the BBB  
Many approaches used to improve drug delivery to the brain have been 
investigated with limited success such as disruption of the BBB (e.g. using 
pharmacological molecules) or non-disruption of the BBB methods (e.g. using 
prodrugs). There are many potential hydrophilic drugs such as peptides and proteins 
that cannot readily cross the BBB via the transcellular pathway due to their 
physicochemical properties (i.e., size, hydrogen-bond potential). One way to improve 
their delivery is to increase their permeation through the paracellular pathways of the 
BBB. The porosities of the paracellular pathways can be increased via disruption of the 
cell-cell adhesion in the intercellular junctions of the BBB. Peptides derived from 
occludins, claudins, and cadherins have been shown to improve delivery of drug and 
marker molecules through the BBB.  
1.2.2 Cadherin Peptides  
Cadherin peptides such as HAV- and ADT peptides derived from the 
extracellular domain of E-cadherin have been shown to disrupt the intercellular 
junctions of biological barriers in cell culture monolayers and in vivo models. HAV 
peptides improved the brain delivery of 14C-mannitol and 3H-daunomycin in an in-situ 
rat brain perfusion model [16]. In addition, the HAV- and ADT-peptides improved BBB 
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permeation of a magnetic resonance imaging (MRI) contrasting agent called 
gadolinium-diethylenetriaminopentaacetic (Gd-DTPA) in mouse and rat as detected by 
MRI.  
1.2.3 Occludin Peptides  
Occludin and claudin peptides have also been shown to improve delivery of 
marker and drug molecules through an in vitro model of the BBB as well as in in vivo 
animal models [17-21]. Occludin peptides derived from extracellular loops of occludin 
in TJ showed ability to perturb the TJ and enhance the paracellular flux for large 
molecules. OCC2 peptide represent second extracellular loop of occludin, able to 
perturb the A6 cell monolayer by decreasing their TEER values in a reversible manner 
and increase the flux of molecules of different sizes such as inulin (5.2 kDa) and dextran 
(40 kDa) [17]. Synthetic occludin peptides (OP) from extracellular loops with different 
sequence numbers showed ability to enhance the 14C-mannitol using Caco-2 cell 
monolayer as a model [18].  For example, C1C2 peptide derived from occludin can 
improve the in vivo delivery of tetrodotoxin (TTX) and opioid peptide (DAMGO) 
through the BBB in the mouse model [20]. 
1.2.4 Claudin Peptides  
The barrier function of claudins in TJ suggested to be more connected to TJ 
barrier permeability than occludins, as knock out occludins in some tissues did not 
change the TJ function. The modulation of claudins in TJ may result in toxic risks, as 
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claudins are target for bacterial toxin, for example, claudin-3 and -4 are targets for 
Clostridium Perfringens enterotoxin [18]. Based on claudin species, claudins derived 
peptidomimetics can be used either to enhance the permeability of the TJ or prevent 
unwanted viruses or toxin entry via TJ. For example, extracellular loop 
peptidomimetics of claudin-1 showed compromise the intestinal barrier in vitro and in 
vivo and a modified peptidomimetic (C1C2; Claudin-158-81) from same region of 
claudin-1 can reversibly decrease the TEER in Caco-2 cell monolayer and enhance the 
MOR-agonists DAMGO or morphine via blood-nerve barrier (BNB) for analgesic effects 
in in vivo model [22]. Differently, CL58 (MANAGLQLLGFILAFLGW) and CL59 
(AFLGWIGAIVSTALPQWR) derived from N-terminus and first transmembrane 
regions of claudin-1 able to minimize the entry of hepatitis C virus (HIV) in in vitro 
model [23]. A synthetic peptides derived from second loop of extracellular domain of 
claudin-4 showed ability to prevent the action of Clostridium Perfringens enterotoxin in 
Caco-2 and in vivo models [24]. 
1.2.5 Effect of Cyclization on Peptides. 
Conformational flexibility of linear peptides can be restricted through cyclization 
processes that might increase the biological activity of these peptides. The high affinity 
of cyclic peptides than linear analogues to receptors might be a result from better 
structural-activity relationships and more favorable entropic effects or increasing in the 
cyclic peptides biological rigidity [25]. Cyclic peptides gain more structural rigidity in 
comparison to linear analogues that may enhance their stability against proteolytic 
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enzymes [26, 27]. Peptides or peptide analogues can be cyclized (intermolecular 
cyclization) by different methods such as making a disulfide bond between two thiol 
groups in cysteine residues, an amide bond between C-terminus and N-terminus or a 
lactam bridge between aspartic or glutamic acid and lysine residues. Moreover, the 
disulfide bridge that can be made by oxidizing thiol groups of the cysteine residues 
occur naturally in proteins or peptides (e.g. insulin and somatostatin) [27, 28].  
1.3 Mechanism of Action of Agents used to Modulate the BBB and Improve the 
Delivery of Molecules through the BBB 
1.3.1 Binding Studies of Peptides and Proteins 
The cell macromolecular components such as proteins are responsible and/or 
involved in many biological functions of the cells. The biological interaction process of 
ligands to proteins may affect on the biological activity of these proteins as some of the 
pharmacological actions occur by binding between ligands and their receptors (i.e. 
proteins) [29, 30]. Exploring ligands interaction to proteins may serve as a basis to 
design bioactive molecules, evaluate the ligands binding affinity to their receptors and 
understanding the proteins biological activity. For example, the interruption of protein-
protein interaction by peptides (ligands) can help to understand the biological function 
of these proteins. Another example, the binding affinity studies usually aims to evaluate 
ligands affinity to their receptors and analyze receptor-ligands mechanism interaction 
[29]. One of the fundamental binding studies is the saturation binding assays as 
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dissociation constant at equilibrium is evaluated by a series of ligand concentrations 
titrated against its receptor. Competition binding assays are used to evaluate the 
cooperativity between two ligands to a receptor [29].  
 
1.3.2 Methods 
There are numerous experimental methods to study the binding assays as some 
of them use labeled ligand or receptors either by radioactive, fluorophores, 
chromophores or isotopes labeling and the other methods do not need to label ligands 
or receptors to perform the assay.  
1.3.2.1 NMR Technique 
Nuclear magnetic resonance (NMR) spectroscopy is a fast and a powerful 
technique to study intermolecular interactions (e.g. receptor-ligand) due to different 
NMR parameters like chemical shifts, linewidths, coupling constants and signal 
intensities are sensitive for nuclei environment. In addition, NMR can measure one or 
more NMR parameters for the binding action as nuclei, residues or secondary structure 
of proteins can be affected. The 1D NMR resolution spectra can be improved by using 
one or two of NMR active isotopes such as 13C, 15N, 19F or 31P  for 2D or 3D-NMR assays 
[31]. 
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1.3.2.2 Other Techniques 
Radioreceptor assays (RRA) require labeling ligands with radioactive isotopes 
such as 3H, 125I or 32P. Although RRA provides sensitivity and specificity, it uses a 
hazardous labeling while fluorescence resonance energy transfer (FRET) requires a non-
radioactive labeling (fluorophore labeling). Isothermal titration calorimetry (ITC) and 
optical biosensors are binding assays methods that do not require labeling for either 
ligands or receptors [32].  In addition to energetics and kinetics information that can be 
provided by pervious binding assays methods, NMR and X-ray spectroscopies can 
provide spatial arrangement of the receptor-ligand complex, which is important to 
identify binding sites and how receptors, for example proteins, structures can be altered 
and changed.  
1.4 Other Strategies used to Improve Delivery of Drugs to the Brain  
1.4.1 Clinical Methods 
1.4.1.1 Osmotic modifiers  
Hypertonic mannitol solution can disrupt the BBB. Studies have shown 25% 
hyperosmolar mannitol solution or hyperosmolar solutions of arabinose, and lactamide 
can be used to temporarily modify the BBB permeability and improve delivery of drug 
molecules.  
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1.4.1.2 Intracerebral implantation 
       One of the direct methods to bypass or avoid the BBB is to implant biodegradable 
polymers contain drugs in brain tissues (brain parenchyma) that give a sustain release 
for drugs in brain tissues. For example Gliadel wafers used for delivering 
chemotherapeutic agents to treat recurrence glioma brain cancer [33]. 
1.4.2 Prodrugs  
Hydrophobic drugs can cross the BBB via the transcellular pathway because they 
can partition to cell membranes [3, 34]. In contrast, hydrophilic drugs cannot cross the 
BBB because they cannot readily partition into the cell membranes [35]. To improve the 
transcellular permeation of hydrophilic drugs, their physicochemical properties have to 
be altered and make them more lipophilic with lower hydrogen-bonding potential to 
favor membrane partition. Pardridge et al. proposed that there is a relationship between 
BBB transport and H-bond potential and/or membrane partition coefficient (PC; i.e., 1-
octanol/Ringer's buffer PC) [36]. For example, progesterone (PC = 1800) with two 
potential hydrogen bonds (H bonds) has higher BBB permeation than cortisol (PC = 35), 
which has eight potential H bonds [36]. It was suggested that each pair of hydrogen 
bonds in a given molecule could decrease BBB permeation by 1 log unit [4]. Later, the 
rule of five was proposed by Lipinski in an attempt to predict successful delivery of 
drugs through the biological barriers; this is based on H-bond potential, molecular 
weight and logP value [37]. Drug molecules with more than five H-bond donors, ten H-
bond acceptors, a molecular weight >500 and a logP of 5 are less likely to be absorbed 
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and/or penetrate the biological barriers [37][10]. Hydrophobic molecules with a high 
molecular weight such as epipodophyllotoxin (MW: 588 Da) and vincristine (MW: 842 
Da) exhibit low brain uptake [38]. 
The formation of a prodrug is one way to alter the physicochemical properties of 
a drug to increase transcellular passive diffusion [34]. In this case, the charged and/or 
polar functional group on the drug can be transiently masked with ester, amide or 
acetylated groups in the prodrug (Figure 1) [34, 39]. The expectation is that the prodrug 
can be converted back to the parent drug by enzymatic and/or chemical reaction within 
the CNS to produce the desired biological activity [39]. Many ester prodrugs have been 
developed to improve brain delivery of drugs; the abundance of esterase enzymes in 
tissues can readily convert the prodrug to drug to exhibit biological activity. Heroin is a 
classic example of a morphine prodrug in which the OH groups in morphine are 
derivatized with acetyl esters. This derivatization gives heroin higher lipophilicity than 
morphine. Enhancement of morphine lipophilicity by masking OH groups with acetyl 
ester gives heroin a brain uptake that is 100-fold higher than morphine, thus a higher 
potency of heroin compared with that of morphine [39]. A similar idea has been 
attempted in which one of the OH groups in morphine is converted to methyl ethers – 
this generates codeine and its brain delivery increased tenfold compared with 
morphine. Both heroin and codeine can be converted to morphine by enzymes in the 
brain parenchyma [39]. In another example, mouse brain uptake of the phenyl ester 
prodrug of nipecotic acid is enhanced compared with that of the parent nipecotic acid 
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(Figure 2) [40]. Similarly, acetorphan, an ester prodrug of thiorphan (enkephalinase 
inhibitor), more effectively crosses the BBB than thiorphan (Figure 2) [41]. Upon 
delivering acetorphan, the parent thiorphan was detected in the rat brain, suggesting 
that the ester prodrug was converted to the drug in the brain [41]. The brain delivery of 
peptides is also hampered by the presence of the BBB because peptides have 
physicochemical properties that are not conducive to partitioning to cell membranes for 
transcellular delivery [35]. Some peptides have charges at the N- and C-termini, and 
most peptides have a high hydrogen-bonding potential to water molecules. To improve 
delivery of peptides through the BBB, their physicochemical properties have to be 
altered to favor membrane partition. One way to alter the physicochemical properties is 
to form cyclic peptide prodrugs (Figure 3). By increasing lipophilicity, lowering 
hydrogen-bonding potential, lowering hydrodynamic radii and increasing secondary 
structure, the formation of cyclic prodrugs of opioid peptides [35] and RGD 
peptidomimetics [42, 43] has been shown to increase transport though the biological 
barriers compared with that of their parent peptides or peptidomimetics. The cyclic 
peptide prodrugs can be converted to the parent opioid peptide or RGD 
peptidomimetic by esterases. In some cases, the formation of cyclic peptide prodrugs 
can also cause recognition by efflux pumps in the biological barriers; this is due to the 
recognition of the chemical linker or the promoiety by the efflux pumps [44]. Important 
considerations for blood-to-brain transport of prodrugs are the rate of prodrug-to-drug 
conversion and the site-selective conversion. This bioconversion in the brain tissues 
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should be fast to allow accumulation or trapping of the parent drug in the brain [39]. By 
contrast, the prodrug-to-drug bioconversion should be slow in the blood to maintain a 
high blood concentration of the prodrug for crossing the BBB. For therapeutic activity in 
the brain, sufficient pharmacological concentration of the parent drug in the brain is 
required; thus, the clearance rate of the prodrug should be close to the rate of 
bioconversion in the brain [39]. The chemical delivery system (CDS) is derived from a 
prodrug technology and it is a conjugate between a targeting moiety (T) and the drug 
(D) to make a T–D conjugate [45]. The chemical delivery system uses a redox conversion 
system as a chemical pathway to trap the T–D conjugate in the brain. The targeting 
moiety increased the lipophilicity of the T–D conjugate to enhance transcellular 
transport across the BBB. After entering the brain, the T in T–D is converted by 
metabolic enzyme to a charged moiety T to give a T–D conjugate. The concentration 
gradient drives the T–D conjugates to cross the BBB and metabolic conversion in the 
brain produces T–D conjugates. Because the T–D conjugate cannot partition to BBB cell 
membranes, the conjugate is trapped and accumulated in the brain. Finally, another 
enzyme reaction converts T–D to release the D and T. 
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Figure 2. Formation of ester prodrugs to improve blood–brain barrier membrane 
permeation of morphine, nipecotic acid and thiorphan. The alcohol group of morphine 
was acetylated to make heroin, which is a 100-fold greater ability to permeate the 
blood–brain barrier than morphine. The carboxylic acid of nipecotic acid was converted 
to phenyl ester with m-nitrophenol to increase its blood–brain barrier permeation. The 
esters can be converted to their parent drugs by esterases in the brain. Acetorphan, the 
phenyl and acetyl ester prodrug of thiorphan, is able to cross the blood–brain barrier; 
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1.4.3 Efflux transporters and their inhibition  
Although the increase in lipophilicity of a prodrug increases brain uptake, the 
increase in lipophilicity can also affect the pharmacokinetic properties of the drug. The 
increase in lipophilicity can lower the plasma concentration owing to the increase 
protein binding and/or drug uptake by peripheral tissues. Therefore, lowering the 
plasma concentration can then proportionally decrease the drug brain uptake [46]. 
Additionally, increasing lipophilicity may increase recognition by efflux pumps such as 
P-glycoprotein (P-gp) receptors [47]. The energy dependent ATP-binding cassette 
family of efflux transporters (i.e., P-gp and MRPs) are localized at the BBB endothelial 
cells and prevent drug molecules from entering the brain [48]. P-gp efflux pumps have 
broad structural recognition, and one potential way to avoid P-gp recognition is to 
remove the P-gp recognition feature(s) on the drug when designing it [48]. However, 
this is difficult to accomplish without altering the biological activity of the drug. A 
prodrug method has been investigated to mask the functional group(s) that is 
responsible for P-gp recognition [39]. One option for overcoming the efflux transporters 
is utilizing P-gp inhibitors such as verapamil. Drug co-administration with inhibitors 
can enhance drug permeation into the brain [39, 48, 49]. It should be noted that these 
inhibitors could induce side effects. As an example, because verapamil is a calcium 
channel blocker for treatment of hypertension, its use for blocking P-gp to enhance BBB 
drug delivery may generate side effects caused by blocking the calcium channel. It 
should be noted that efflux transporters play an important role in clearing brain 
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metabolites and toxic molecules from the brain; therefore, prolonged treatment with the 
efflux inhibitors may lead to unfavorable side effects [48]. A better way to use a P-gp 
inhibitor is by designing out the other biological activity. A good example of this is 
cyclosporine D; it inhibits P-gp without immunosuppressive activity. By contrast, 
cyclosporine A has both immunosuppressive activity and efflux pump inhibitory 
activity [50, 51]. Recently, a dimer prodrug of an HIV protease inhibitor (abacavir) was 
designed to inhibit P-gp as well as to increase BBB drug permeation for treating 
accumulated HIV in the brain [52]. The abacavir dimer was conjugated via a disulfide 
bond through a promoiety that can release the abacavir after reduction of the disulfide 
bond (Figure 4). The rationale to form a dimer was that P-gp has multiple substrate 
recognition sites. The idea is that each unit of the dimer fills two different sites on P-gp 
to effectively block its activity while allowing the unbound dimer molecules to 
penetrate the BBB. The hope is that after the dimer prodrug enters the brain it can be 
converted to a monomer upon reduction of the disulfide bond. The abacavir dimer 
improved the uptake of NBD-abacavir, calcein-AM, and I-iodoarylazidoprazosin in T-
lymphoblastiod cells that have overexpression of P-gp. This suggests that the abacavir 
dimer binds to P-gp. The concept of prodrug dimers has been used in galantamine [53] 
for potential treatment of Alzheimer's disease; its mechanism of action to block P-gp 
was evaluated in a cell culture system similar to that of the abacavir dimer. 
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Figure 3. The cyclic prodrugs were formed using acyloxy-alkoxy, phenyl propionic acid, 
coumarinic acid and oxymethyl-modified coumarinic acid promoieties. The prodrugs 
can be converted to the parent drugs upon esterase cleavage reaction followed by 
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Figure 4. The conversion of the abacavir dimer prodrug for effective inhibition of P-
glycoprotein to improve delivery of abacavir into thebrain. The dimer can be converted 
into the abacavir monomer upon reduction of the disulfide bond followed by a 
cyclization reaction of the promoiety. 
 
1.4.4 Utilizing carrier-mediated transport system 
Most nutrients (i.e., glucose, mannose, amino acids, nucleosides and vitamins) 
that are essential for the brain are polar molecules that cannot pass through the BBB via 
passive diffusion. These nutrients utilize specific transporter(s) at both the luminal and 
abluminal sides of the BBB for their entry into the brain [39, 54, 55]. These transporters 
have been exploited to enhance drug delivery into the brain [54, 56]. A large neutral 
amino acid transporter (LAT1) [57-59] and a glucose transporter (GLUT1) [60-62] have 
been used to transport drugs across the BBB by conjugating the drug to an amino acid 
or glucose, respectively (Figure 5) [39, 56, 63]. Conjugates of ketoprofen and 
indomethacin with D-glucose were transported by GLUT1 receptors across biological 
barriers [61]. Ketoprofen-lysine and 6-mercaptopurine-L-Cys were used to target LAT1 
transporters for improving brain delivery of ketoprofen and 6-mercaptopurine, 
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respectively (Figure 5) [57, 58]. An in situ rat brain perfusion study showed that the 
ketoprofen-lysine prodrug crossed the BBB via a LAT1-mediated transport mechanism. 
6-mercaptopurine-L-Cys can also inhibit the cellular uptake of C-L-Leu, a substrate for 
LAT1 transporters; this suggests that LAT1 transporters mediate the uptake of 6-
mercaptopurine-L-Cys. Similarly, acyclovir and zanamivir were linked to valine to give 
valacyclovir and Zan-L-Val prodrugs, and they have been shown to cross the intestinal 
mucosa barrier utilizing an hPepT1 receptor [64, 65]. 
 
 
Figure 5. The formation of prodrugs with ligands to target cell surface receptors such as 
amino acid and glucose transporters Some of the prodrugs have a linker between the 
drug and targeting ligand as shown in Zan-L-Val, valacyclovir and indomethacin-
linker-glucose. Some prodrugs, such as ketoprofen-lysine, S-6-(purinyl)-L-cysteine, 
 24  
pNO2-Phe-L-Glu, d-MOD-L-Glu, ketoprofen-glucose and indomethacin-glucose,have a 
direct connection between the drug and targeting ligand. 
1.5. Thesis and Chapters Goals 
1.5.1 Overall goals of the thesis     
The overall goals of the thesis are to deliver marker, diagnostic or drug 
molecules to the brain by modulating the BBB using synthetic cadherin peptides, 
understand how might these modulator peptides can work, bind and evaluate their 
affinity to first domain of E-cadherin.  
1.5.2 Chapter 2  
The goal of this project is to make more active and stable synthetic cadherin 
peptides for the BBB modulating purposes by cyclization linear synthetic cadherin 
peptides that showed modulation activity in different BBB models. The cyclic HAV 
(cHAVc3) peptide showed better activity and stability than linear HAV (HAV4) peptide 
for enhancing marker molecules delivery to the brain using in vitro and in vivo models 
of the BBB.  
1.5.3 Chapter 3  
The goals of this project are to probe cHAVc3 peptide interaction with EC1 
domain of human E-cadherin by determining the affinity and potential binding sites of 
cHAVc3 peptide to the EC1 domain using NMR and moleucular modeling (i.e., 
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molecular dynamics and molecular docking simulations). Cyclic cHAVc3 peptide binds 
to residues F77, S78 on EC1 with intermediate dissociation constant (0.5–7.0 X 10-5 M).  
1.5.4 Chapter 4 
The goals of this project are to investigate the binding sites and dissociation 
constants (Kd) for ADT and HAV peptides (synthetic cadherin peptides) using docking 
technique and NMR data. The binding sites of three ADT peptides on the EC1 domain 
are approximately in one region while HAV6 peptide showed binding to a different 
region, which was around to the binding region of cyclic HAVc3 site. Although these 
synthetic cadherin peptides fall in weak binding range to EC1 domain, ADTc7 and 
ADTc5 peptides showed higher in binding affinity ten times than ADTc9 and HAV6 
peptides.   
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2.1 Introduction 
It is challenging to treat brain diseases such as Alzheimer’s and Parkinson’s and 
brain tumors because drugs used to treat these disorders have difficulty in crossing the 
blood-brain barrier (BBB) [1-3].  The microvascular endothelial cells of the brain have 
tight junctions that limit paracellular diffusion [3] and there are various efflux transport 
proteins (P-glycoprotein, breast cancer resistance protein, multidrug resistance-
associated proteins) and metabolic enzymes that reduce transcellular routes of entry to 
the brain [4-6].  To cross the BBB, the drug molecule must have optimal 
physicochemical properties; for example, many large molecules such as peptides and 
proteins cannot readily cross the BBB due to their size and hydrophilicity [1, 3, 7].  For 
example, nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) 
have been investigated to treat neurodegenerative diseases [8-13]. Unfortunately, as 
with other proteins, the brain delivery of NGF and BDNF is challenging. Therefore, 
there is a need for safe and effective methods to improve the delivery of proteins and 
peptides to the brain.  
Modulation of the BBB paracellular pathway is one way to improve brain 
delivery of proteins and peptides. Blood-brain barrier modulation can be achieved in a 
variety of different ways; one example is the use of vasoactive agents (i.e., bradykinin, 
bradykinin analogs, histamine, lysophosphatidic acid) to disrupt the BBB [14].  
However, these agents produce their effects through activation of receptors on the brain 
endothelial cells and can potentially cause rapid desensitization, pathological changes 
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in receptor density, and damage to the BBB [14].  Infusion of hyperosmolar mannitol 
(25% solution) has also been used to temporarily open the BBB tight junctions to allow 
both lower (i.e., methotrexate) and higher molecular weight (i.e., Evan blue-albumin) 
molecules to enter the brain [15, 16]. 
A more selective method to modulate the paracellular pathway of the BBB uses 
peptides to inhibit protein-protein interactions in the intercellular junctions of the BBB. 
Examples include inhibitory peptides targeting claudin-1 (i.e., C1C2 peptide) and 
occludin (i.e., OCC1 and OCC2 peptides) that modulate tight junctions in various in 
vitro models of the BBB [17, 18] and increase the brain delivery of the opioid receptor 
agonist [D-Ala2, N-MePhe4, Gly5-ol]-enkephalin (DAMGO) [19].  In the case of C1C2 
peptide, the mechanism of action involves relocalization of claudin-1 from the cell 
surface to cytosol, resulting in a long-lasting modulation of the BBB [20, 21].  Our work 
has focused on cadherin peptides that modulate cadherin interactions in the adherens 
junctions of both endothelial and epithelial cells. The His-Ala-Val (HAV) and Ala-Asp-
Thr (ADT) peptides derived from the extracellular-1 (EC-1) domain of E-cadherin have 
been shown to enhance delivery of 14C-mannitol in vitro in Madin-Darby canine kidney 
(MDCK) cell monolayers [22, 23]. Recently, both HAV6 (Table 1) and ADTC5 peptides 
have been shown to enhance the brain delivery of both small and large molecules into 
the brain of rats and mice [24-26]. 
In this study, cyclic HAV peptides (cHAVc1 and cHAVc3) were designed to 
improve BBB modulatory activity compared to that of linear HAV4 peptide (Table 1). 
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The hypothesis was that the increased backbone rigidity provided by cyclic HAV 
peptides would result in improved binding affinity for the extracellular domain of 
cadherin as well as improved plasma stability compared to that of the linear peptide. 
Therefore, cyclic HAV peptides (i.e., cHAVc1, cHAVc3) were synthesized by forming a 
disulfide bond between two cysteine residues added to the N- and C-termini of the 
original linear peptide (Table 1). The plasma stabilities of linear HAV4 and cyclic 
cHAVc3 peptides were determined in rat plasma, and the peptide degradation was 
detected and quantified by mass spectrometry. The adherens junction modulatory 
activity of cyclic cHAVc3 peptide was compared to that of linear HAV4 using in vitro 
MDCK cell monolayers, and the modulatory effects on BBB permeability were 
examined using the in-situ rat brain perfusion model as well as in the in vivo Balb/c 
mouse model. The results indicated that cyclic cHAVc3 peptide has better BBB 
modulatory activity and plasma stability than does the linear HAV4 peptide.  
	  
2.2 Material and Methods 
2.2.1 Peptide Synthesis 
Cyclic and linear HAV peptides were synthesized using solid-phase method 
with Fmoc chemistry in a Perceptive Pioneer Peptide synthesizer as previously 
described [22, 23]. HAV peptides were cleaved from resin and purified by reversed-
phase HPLC using a C18 column. The disulfide bond in cyclic peptides was formed by 
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bubbling air into a dilute solution of precursor linear peptides in ammonium 
bicarbonate buffer at pH 8.5. The identity of each peptide was determined by mass 
spectroscopy. 
 
2.2.2 In Vitro Peptide Modulatory Activity in MDCK Cell Monolayers 
2.2.2.1 Cell Culture: 
The in vitro modulatory activities of linear and cyclic HAV peptides were 
evaluated in MDCK cell monolayers and this model was selected to evaluate the effect 
of cadherin peptides in modulating the intercellular junctions of the cell monolayers. 
The MDCK-II cells (cat.# 00062107) were acquired from ECACC, Salisbury, UK and 
were seeded into Corning flasks until they reached 80% confluency as a monolayer. 
Then the cell monolayer was washed twice with PBS followed by treatment with 
trypsin-EDTA solution (0.25% trypsin, 1.0 mM EDTA in Hank's Balanced Salt Solution 
(HBSS)). The detached single cells were then resuspended, collected, and counted. They 
were then added into each well (75,000 cells/well) of a Transwell® plate (Permeable 
Supports, 0.4 µM polyester membrane, 12-well plates) and were incubated for 5–8 days. 
TEER values were measured before and at the day of the experiment to check the 
monolayer integrity. 
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2.2.2.2 Inhibition of Junction Resealing:  
The inhibition of junction-resealing in MDCK-II cell monolayers was used to 
compare the modulatory activity of linear and cyclic HAV peptides [23]. In this study, 
the changes in TEER values were followed using an EVOM™ voltohmmeter (World 
Precision Instruments) in the presence and absence of HAV peptides. Each experiment 
was started at TEER values of 280–320 ohm.cm2 for the monolayers. After the cell 
monolayers were confluent, they were washed with HBSS solution containing 25 mM 
glucose, 2 mM CaCl2, 0.75 mM MgSO4, and 10 mM HEPES. The cell monolayers were 
incubated with HBSS for 1.5 h, and the TEER values were recorded. Then the cell 
monolayers were washed and incubated with Ca2+-free buffer to open the tight 
junctions. The intercellular junction opening caused a decrease in TEER values of 50–
60%. The cells were then incubated in Ca2+-sufficient medium to reseal the intercellular 
junctions in the presence and absence of HAV peptides (1.0 mM) on the apical and 
basolateral sides. During the resealing of the intercellular junctions, the TEER values 
were recorded every hour for 6–8 h. 
. 
2.2.2.3 Direct Junction Modulation: 
The activities of HAV peptides were evaluated by directly modulating intact 
MDCK-II cell monolayers. In this assay, only Ca2+-sufficient buffer was used. The 
Transwells were washed with HBSS buffer containing 25 mM glucose, 2 mM CaCl2, 0.75 
mM MgSO4 and 10 mM HEPES. The MDCK cell monolayers were incubated with and 
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without HAV peptides (1.0 mM) on the apical and basolateral sides followed by 
measurement of TEER values every hour for 6–8 h.  
.  
 
2.2.3 Peptide Stability in Rat Plasma 
The rat plasma (lot. no. 19595; NaHeparin) used for plasma stability studies was 
purchased from Innovative Research, Inc., Novi, Michigan. The plasma degradations of 
cyclic cHAVc3 and linear HAV4 were determined using LC-MS/MS, and the half-life of 
each peptide in plasma was calculated. Briefly, HAV4 or cHAVc3 peptide in 1.2 µL of 
DMSO was added into 200 µL of rat plasma to make the final concentration of DMSO 
0.6%. Each peptide solution in rat plasma was incubated and agitated using an orbital 
shaker at 50 rpm at 37 °C for up to 2–3 half-lives, which were 72 h for cyclic cHAVc3 
and 8 h for linear HAV4. The peptides were extracted from plasma using liquid-liquid 
extraction. In this case, 201.2 μL of plasma containing peptide was added into a 1.0 mL 
solvent mixture of ACN:H2O:EtOAc (6:1:1) to precipitate plasma proteins; this was 
followed by centrifugation at 17226 g (12000 PRM) using Centrifuge-5415D (Eppendorf 
AG-22331 Hamburg, Germany). The supernatant was collected and evaporated under 
nitrogen at moderate temperature (35 °C). The resulting residue containing HAV 
peptide was resuspended in 1 mL of a solution mixture of 14% ACN and 1% formic acid 
(FA) in water. Then, 2% heptafluorobutyric acid (HFBA) was added as an ion-pairing 
agent to enhance the partitioning of HAV peptides in a C-18 column (dimensions: 150 × 
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2 mm; pore size, 100 Å; particle size, 5.0 µm). The internal standard for cHAVc3 was 
HAV4 (~300 µM) while the internal standard for HAV4 was 58 µM cHAVc3. 
2.2.4 In-Situ Rat Brain Perfusion 
The in-situ rat brain perfusion studies were done following the previous method 
developed by Takasato et al. [27]. and using three groups of Sprague-Dawley rats for 
vehicle, linear HAV4 and cyclic cHAVc1 peptide. The protocol to perform the animal 
studies was approved by the IACUC at The University of Kansas (AUS#75-05). Before 
starting the animal surgery, the rats were anesthetized by administration of 100 mg/kg 
ketamine and 5 mg/kg xylazine via the intraperitoneal route. A cannula was inserted 
into the left common carotid artery (LCCA) for perfusion of the brain microvessels with 
vehicle or peptide solution (1.0 mM) at a flow rate of 5.0 mL/min. For ligation of the left 
common carotid artery (LCCA), a surgical silk thread was used to encircle the artery 
while the pterygopalatine, occipital, and superior thyroid arteries were coagulated and 
cut. Then the LCCA was catheterized with a polyethylene catheter (PE-50) for 
retrograde perfusion with a heparinized saline (100 IU/mL). The perfusion was started 
immediately after a cardiac puncture under anesthesia. The perfusion protocol was 
carried out as follows: 20-s pre-perfusion with saline, 240-s perfusion with peptide or 
vehicle, 240-s perfusion of 14C-mannitol and 5-s post-perfusion of wash with saline. The 
perfusate was sterilized by filtration and placed in an incubator for oxygenation with 
95% air and 5% CO2 at 37 °C. Throughout the experiment, the rectal temperature was 
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kept at 36.5 ± 0.5 °C using a heat lamp with a monitoring device (YSI model 73 ATD 
indicating controller) [24].  
 
2.2.5 In Vivo Studies  
2.2.5.1 MRI Studies:  
The activities of cyclic cHAVc3 and linear HAV4 peptides in modulating the BBB 
were compared in adult Balb/c mice. The animal study protocol to detect brain delivery 
and deposition of Gd-DTPA with and without HAV peptides followed with detection 
using MRI was approved by the IACUC at the University of Manitoba (Number 11-
069). A previous MRI procedure by On et al. to monitor the BBB permeability was used 
in this study [28]. The enhancement of Gd-DTPA brain deposition caused by cHAVc3 or 
HAV4 peptides was determined using MRI pixel intensities of the brain images. Before 
administration of Gd-DTPA, T1- and T2-weighted brain images were obtained as 
background [25]. Then Gd-DTPA (0.4 mmol/kg) along with cHAVc3 (0.001–0.10 
mmol/kg), HAV4 (0.001–0.10 mmol/kg), or PBS was administered via tail vein. Every 3 
min, a T1-weighted image was obtained up to 21-min imaging session followed by a 
second dose of Gd-DTPA at 21 time; then, T1-weighted images were collected every 3 
min for another 21-min. Marevisi 3.5 software (Institute for Biodiagnostics, National 
Research Council, Ottawa, Ontario, Canada) was used to quantified the intensity of Gd-
DTPA in the brain at the outlined regions of interest (ROI) within coronal brain slices. 
 43  
Paravision 3.0 software package was used to quantify the percent difference of Gd-
DTPA in the images of brain slices using following equation: 
[(post-Gd-DTPA T1-weighted images – T1-weighted images of pre-Gd-DTPA) /pre- 
Gd-DTPA T1-weighted images] × 100 
The percent difference analysis was expressed as fold-enhancement of Gd-DTPA at 
different time intervals. 
To determine the duration of BBB modulation achieved with the cadherin 
peptides, Gd-DTPA contrast MRI experiments were performed following various 
pretreatment periods. The dose of each peptide was 0.01 mmol/kg and the dose of Gd-
DTPA was 0.4 mmol/kg. Three groups of mice were administered with vehicle, 
cHAVc3, or HAV4, respectively, via i.v. 1 h prior to administration of Gd-DTPA 
followed by an MRI imaging session.  Another three groups of mice were injected i.v. 
with vehicle, cHAVc3, or HAV4, respectively, 2 h prior to i.v. administration of Gd-
DTPA followed by MRI imaging of the brain. Finally, two groups of mice were 
administered vehicle and cHAVc3 via i.v. 4 h prior to the administration of Gd-DTPA 
followed by brain imaging with MRI. 
2.2.5.2 NIR Imaging Studies:  
The BBB permeability increases for a large molecular weight compound and a P-
glycoprotein (P-gp)-sensitive agent cause by HAV peptide were also determined using 
NIRF imaging agents [25, 28, 29].  IRDye 800CW PEG (0.01 µmol/kg), a pegylated dye 
of approximately 25 kDa molecular weight, and  R800 (0.032 µmol/kg) as P-gp substrate 
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were delivered and detected in the brain using NIRF [6, 30]. These marker molecules 
were delivered via i.v, route into mice in  three different treatment regimens. In 
treatment regimen A, the mice received only vehicle injection (PBS); in treatment 
regimen B, they received 0.010 mmol/kg of cHAVc3; in treatment regime C, they 
received 0.010 mmol/kg of HAV4. Twenty minutes after treatment, cardiac perfusion of 
10% formaldehyde solution was delivered to sacrifice the mice. Then, the brain was 
removed NIRF analysis and the deposition of NIRF dye in the brain was determined ex 
vivo using an Odyssey near-infrared imaging system (Licor, Lincoln, NE). For 
quantitative determination, the fluorescence intensity at ROI from the tissue was 
normalized to fluorescence from the blood sample at the same time point. The results 
were presented as relative fluorescence units per unit of tissue divided by relative 
fluorescence units per microliter of blood. 
2.3 Results 
2.3.1 Modulatory Activity Comparison between Linear HAV4 and Cyclic cHAVc1 
Peptides  
The activity of linear and cyclic peptides in inhibiting junction resealing was 
evaluated using MDCK cell monolayers. In this experiment, the cell monolayers were 
treated with calcium-free medium, resulting in the opening of intercellular junctions 
and a decrease in TEER values for the cell monolayers. After one hour, calcium-free 
medium was replaced with calcium-containing medium to reseal the intercellular 
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junctions. The junction resealing was reflected by the steady increase in the TEER 
values of the cell monolayers measured over time. To evaluate cadherin peptide 
activity, the peptide was added into the calcium-containing medium prior to addition 
into the disrupted cell monolayers. Both the linear HAV4 and cyclic cHAVc1 peptides 
at 1.0 mM significantly inhibited the resealing of the intercellular junction compared to 
HBSS control, and both peptides had the same activity (Figure 1A). At various 
concentrations (20 to 800 µM) and measuring %Δ TEER between the 2-h and 5-h time 
points, cHAVc1 inhibited the resealing in a concentration-dependent manner and 
significant inhibitory activity was observed as low as 40 µM (Figure 1B). 
The in-situ rat brain perfusion studies were used to compare the efficacy of linear 
HAV4 and cyclic cHAVc1 in enhancing brain transport of 14C-mannitol compared to 
vehicle (Figure 1C). Both linear HAV4 and cyclic cHAVc1 peptides significantly 
enhanced the passage of 14C-mannitol into the rat brain compared to vehicle (Figure 
1C). However, as observed in the in vitro junction annealing assay, there was no 
significant difference in the BBB permeability of 14C-mannitol caused by linear HAV4 
and cyclic cHAVc1 peptides.  
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Figure 1:  Modulatory activity comparison of linear HAV4, cyclic cHAVc1, and HBSS in 
MDCK cell monolayers. (A) Comparison of peptide activities to inhibit junction 
resealing. At 5- and 6-h time points, both linear HAV4 and cyclic cHAVc1 peptide 
significantly inhibited the junction resealing compared to HBSS (*, p = 0.011 for HAV4 
vs. HBSS; #, p = 0.035 cHAVc1 vs. HBSS). There was no significant difference in the 
activity of linear HAV4 and cyclic cHAVc1 peptides. (B) The concentration-dependent 
activity of cHAVc1 peptide at 20–800 µM determined as %D TEER value. The %D TEER 
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concentration and %D TEER of HBSS was set at 100%. (*) considered significant change 
with p < 0.013. (C) The effect of cHAVc1 and HAV4 in increasing brain delivery of 14C-
mannitol in the in-situ rat brain perfusion model. Both linear HAV4 and cyclic cHAVc1 
peptides significantly enhanced 14C-mannitol transport to the brain compared to vehicle 
(*, p < 0.05). No difference was observed in the delivery enhancement of 14C-manitol by 
HAV4 and cHAVc1.  
2.3.2 Modulatory Activity Comparison between Linear HAV4 and Cyclic cHAVc3 
Peptides 
Both HAV4 and cyclic cHAVc3 peptides inhibited the junction resealing of 
MDCK cell monolayers compared to HBSS-treated controls (Figure 2A).  However, 
cHAVc3 was a significantly better inhibitor of junction resealing than HAV4; at the 5- 
and 6-h time points, the cHAVc3-treated cells had lower TEER values than those of 
HAV4-treated cell monolayers. Next, the activities of these peptides were compared in 
the intact MDCK cell monolayers (Figure 2B). At the 7- and 8-h time points, both HAV4 
and cHAVc3 peptides lowered the TEER values significantly compared to HBSS (Figure 
2B). In addition, the cHAVc3 peptide had significantly better modulatory activity than 
HAV4 peptide at the 7- and 8-h time points. The cHAVc3 peptide was active in a 
concentration-dependent manner; the modulatory activity of 1000 μM peptide was 
significantly different from that of 500 μM peptide, and the activity of 500 μM peptide 
was significantly different than that of HBSS (Figure 2C). 
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Figure 2:  Modulatory activity comparison of linear HAV4, cyclic cHAVc3, and HBSS in 
MDCK cell monolayers. (A) Comparison of peptide activities to inhibit junction 
resealing. Cyclic cHAVc3 peptide has significantly higher activity than linear HAV4 
peptide at the 6-h time point.  (##) p = 0.029, cHAVc3 vs. HAV4; #, p = 0.002 cHAVc3 vs. 
HBSS. (B) Junction modulatory activity of linear HAV4 and cyclic cHAVc3 peptide in 
normal MDCK cell monolayers. Both peptides significantly decreased the TEER values 
compared to HBSS at time points 7- and 8-h.  (*) considered significantly different, 
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0.001). (#) considered significantly different, cHAVc3 vs. HAV4 (#, 7- and 8-h, p = 0.009). 
(C) The effect of concentrations of cHAVc3 in lowering the TEER values (% TEER 
change) at 7-h time point (*, p = 0.001 vs. 1000 µM; **, p = 0.003, 0 vs. 500 µM; #, p = 
0.012 500 vs. 1000 µM). 
 
2.3.3 Plasma Stability Comparison of Linear HAV4 and Cyclic cHAVc3 Peptides  
The in vitro plasma stabilities of HAV4 and cHAVc3 peptides were determined in 
rat plasma using LC/MS-MS. Linear HAV4 degraded faster than cyclic cHAVc3—2.4 h 
and 12.95 h, respectively (Figure 3). These results suggest that cyclization increases 
peptide backbone rigidity, which suppresses enzymatic degradation of HAV peptides 
in plasma.  
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Figure 3: The stability of linear HAV4 (▲) and cyclic cHAVc3 (■) peptides in rat plasma. 
Peptides were detected using LC-MS/MS to quantify the half-lives.  The results 
indicated that the half-life of linear HAV4 peptide (▲) is 2.4 h with kd = 0.2858 ± 0.0162, 
and the half-life for cyclic cHAVc3 peptide (■) is 12.9 h with kd = 0.053 ± 0.0016. The 
extraction efficiency for cHAVc3 is 92.94% and for HAV4 is 101.0%. 
2.3.4 Comparison of HAV4 and cHAVc3 Peptides in Enhancing Brain Delivery of Gd-
DTPA 
The in vivo effects of HAV4 and cHAVc3 peptides on the brain delivery of Gd-
DTPA were determined using MRI throughout a 42-min brain imaging session (Figure 
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brain delivery were monitored in the posterior, midbrain, and anterior regions of the 
brain and were compared to those of mice receiving vehicle (PBS). In mice receiving 
vehicle, minimal amounts of Gd-DTPA were detected in the brain, resulting in mostly 
dark images except for the ventricle regions observed in mid-brain coronal slices 
(Figure 4A).  The white/grey areas in the MRI images following peptide treatment 
represent areas of the brain having increased deposition of Gd-DTPA contrast agent 
(Figure 4A). Treatment with either the linear HAV4 or the cyclic cHAVc3 peptides 
rapidly enhanced the brain deposition of Gd-DTPA, with increases in brain deposition 
observed as early as 3 min following the Gd-DTPA+peptide administration (Figure 4B-
G). The effect on BBB permeability was dose-dependent for both the linear and cyclic 
cadherin peptides. For both peptides, the highest brain deposition of Gd-DTPA was 
found in the posterior region followed by the midbrain and subsequently the anterior 
region (Figure 4B-G). At 0.010 mmol/kg in posterior region, the maximum 
enhancement of Gd-DTPA compared to the background at the 0 time point was up to 
fivefold for linear HAV4 peptide and about eightfold for cyclic cHAVc3 peptide while 
the maximum deposition when treated with vehicle was 2.5-fold.  
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Figure 4: The effects of HAV4, cHAVc3, and vehicle on enhancing brain deposition of 
Gd-DTPA after i.v. administration in Balb/c mice. (A) Representatives of brain 
deposition of Gd-DTPA shown as T1-weighted MR images for the posterior region of 
the brain at 0- and 30-min time points after adminstration of Gd-DTPA (0.4 mmol/kg) 
with vehicle and 0.001 mmol/kg of peptides (HAV4 and cHAVc3). The red arrows 
indicate the brain depositions of the contrast agents. (B–G) The effects of (B–D) linear 
HAV4 peptide and (E–G) cyclic cHAVc3 peptide on the fold-enhancement of Gd-DTPA 
brain vs. time of imaging at (B, E) posterior, (C, F) midbrain, and (D, G) anterior regions.  
The area under the curve (AUC) for Gd-DTPA contrast enhancement in the brain 
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(Figure 5). For HAV4 treatment group at the posterior and anterior regions, the AUCs 
of Gd-DTPA deposition were significantly higher than those of the vehicle group at all 
peptide doses examined; however, for the midbrain, only treatment with 0.01 mmol/kg 
showed significant enhancement compared to vehicle (Figure 5A). In addition, the 
effects of different HAV4 peptide doses could be distinguished in the anterior part of 
the brain but not in the other regions (i.e., posterior and midbrain).  For cHAVc3 
peptide, all peptide doses were significantly better than control in the posterior and 
midbrain regions. In the posterior region, the effect of each dose was significantly 
different from the others (Figure 5B). In the anterior region, only the highest peptide 
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Figure 5: The effect of peptide dose (0.001, 0.0032, 0.01 mmol/kg) on the area under the 
curve (AUC) for Gd-DTPA fold-enhancement at the posterior, midbrain, and anterior 
regions for the entire 42-min session as a result of BBB modulation with (A) linear 
HAV4 and (B) cyclic cHAVc3 peptides (* represents p < 0.05 between peptide and 
vehicle; ‡ represents p < 0.05 between two different concentrations).  (C) Comparison of 
AUC of Gd-DTPA in the brain posterior after treatment with HAV4 (0.01 mmol/kg), 
cHAVc3 (0.01 mmol/kg), and vehicle (* represents p < 0.05 between peptide and 
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2.3.5 Effect of Linear HAV4 and Cyclic cHAVc3 Peptides on the Duration of BBB 
Disruption 
The duration of BBB disruption caused by each peptide was examined by 
administration of 0.01 mmol/kg of either HAV4 or cHAVc3 peptides at various 
pretreatment times (Figure 6). The AUCs of Gd-DTPA over a 42-min imaging period 
were plotted to compare the treatment effects following administration of vehicle, 
HAV4, or cHAVc3. When Gd-DTPA was delivered immediately after treatment with 
peptide or vehicle, there were clear increases in Gd-DTPA brain depositions in the 
posterior (Figure 6A), midbrain (Figure 6B), and anterior (Figure 6C) regions for both 
peptide treated groups (i.e., HAV4, cHAVc3) compared to the control group. However, 
administration of Gd-DTPA following a 1- or 2-h pretreatment with HAV4 did not 
produce any Gd-DTPA enhancement in any regions of the brain examined. In contrast, 
both the 1-h and 2-h cHAVc3 pretreatments caused significant enhancement of the Gd-
DTPA contrast agent in all three brain regions. Only those mice receiving the 4-h 
pretreatment with cHAVc3 showed no significant increase in contrast enhancement 
compared to vehicle-treated control mice (Figure 6). These results demonstrate that the 
time frame for BBB modulation is longer for cHAVc3 than for HAV4 peptide.     
The extent of BBB modulation with large macromolecules and drug efflux 
transport substrates was also examined using NIRF imaging agents IRdye800cw-PEG 
and R800, respectively. In these studies, mice were pretreated with the peptide and, 
after 5 min or 1 h, R800 and IRdye800cw-PEG were delivered and the brain deposition 
 63  
of these molecules was quantitatively assessed using ex vivo brain images. Following 5-
min pretreatment with both linear HAV4 and cyclic cHAVc3 peptides, the brain 
deposition of IRdye800cw-PEG was higher than in saline-treated controls (Figures 7A-
B). However, the brain delivery of efflux pump substrate R800 was not enhanced by 
either peptide at the 5-min time point. After pretreatment with both peptides for 1 h, 
there were no significant differences in brain deposition of either IRdye800cw-PEG or 
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Figure 6: Comparison of length of BBB modulation by linear HAV4 and cyclic cHAVc2 
peptides at 0.01 mmol/kg dose as measured by the AUC of Gd-DTPA brain deposition 
as a function of time in the (A) posterior, (B) midbrain, and (C) anterior regions. The 
brain depositions of Gd-DTPA were evaluated at different time points for HAV4 
(immediately, and following 1-h, and 2-h pretreatment) and cHAVc3 (immediately, and 





















































 67  
 
Figure 7: The effects of time and characteristics of marker molecules such as IR-dye-
800cw PEG and R800 on their brain deposition when the BBB was modulated with 
HAV4 and cHAVc3 peptides (0.01 mmol/kg). The brain images (A, C) and brain-to-
plasma fluorescence ratio (B, D) of marker molecules when the marker molecules were 
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2.4 Discussion 
The identification and development of methods to improve the delivery of 
molecules into the brain for diagnosis and treatment of brain diseases is a major 
challenge. This study was focused in evaluating the effect of linear (i.e., HAV4) and 
cyclic HAV peptides (i.e., cHAVc1 and cHAVc3) in modulating the intercellular 
adherens junctions using both in vitro cell culture models and in vivo BBB models. The 
hypothesis for these studies is that HAV peptides bind to E-cadherin and disrupt E-
cadherin-mediated cell adhesion in the intercellular junctions, resulting in increased 
paracellular porosity of the BBB. HAV4 is a derivative of HAV6 in which the Ser5 
residue in HAV6 was mutated with the Ala5 residue (Table 1) [22]. The sequence of 
HAV6 peptide was derived from the original sequence (SHAVSS) of extracellular 1 
(EC1) domain of human E-cadherin. This original sequence is conserved in the E-
cadherin from different species such as canine, human, murine and chicken [31, 32]. 
Based on the previous studies in MDCK monolayers, HAV4 displayed better 
modulation of the intercellular junctions of MDCK cell monolayers [22]. Similarly, 
HAV4 peptide enhanced the in vivo brain delivery of Gd-DTPA better than HAV6 in 
Balb/c mice as detected by MRI [26]. 
The formation of cyclic peptides has been shown to increase the peptide receptor 
binding selectivity and biological activity. For example, the antimicrobial activity of 
cyclic peptide BPC194 is higher than that of linear peptide BPC193 [33]. Similarly, a 
cyclic RGD peptide (e.g., cyclo(1,5)KRGDf) was specific toward integrin receptors αvβ3 
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and αvβ5 while a linear RGD peptide was not [34]. Furthermore, formation of cyclic 
peptide has been shown to improve chemical stability as well as plasma proteolytic 
stability of peptides. The chemical stability of cyclic RGD peptide was higher than 
linear RGD peptide in solution close to neutral pH = 7.0 [35]. In the present study, a 
cyclic peptide, derived from the linear HAV-based sequence, was formed to induce 
peptide backbone rigidity, increase binding selectivity to target the extracellular domain 
of the E-cadherin protein, and enhance BBB modulatory activity in vitro and in vivo.   
Initially, the cyclic cHAVc1 peptide was designed and synthesized based on the 
linear HAV4 sequence with addition of cysteine residues at both N- and C-termini to 
make a cyclic octapeptide (Table 1). A disulfide bond was formed upon oxidation of 
thiol groups between the Cys1 and Cys8 residues. Examination of intracellular junction 
modulation in MDCK cell monolayers showed no significant difference in activity 
between cHAVc1 and HAV4 (Figure 1A). However, the cHAVc1 peptide did display 
concentration dependency with an IC50 of approximately 80 µM (Figure 1B).  In this 
assay, the monolayers were first treated with Ca2+-deficient medium to open the 
intercellular junctions and then exposed to the peptides and Ca2+-containing medium to 
examine re-establishment of intracellular junctions and TEER values. Thus, although 
cHAVc1 could have better cadherin-binding affinity than HAV4, the larger size of 
cHAVc1 compared to HAV4 may have impeded its permeation through the tight 
junctions and influenced its ability to modulate the cadherin-cadherin interactions. 
However, as both the HAV4 and cHAVc1 peptides produced similar increases in the 
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BBB permeability of 14C-mannitol in the in-situ rat brain perfusion experiments where 
the junctions are intact, differences in the abilities of the peptides to access the adherens 
junction appears unlikely.  A more plausible explanation for the similar efficacies 
observed with the linear HAV4 and cyclic cHAVc1 peptides is that the large ring size of 
cyclic cHAVc1 did not impose sufficient backbone rigidity to enhance selectivity and 
affinity for targeting of E-cadherin protein.  
In contrast to cHAVc1, cyclic cHAVc3 had better activity than linear HAV4 in 
inhibiting resealing of the intercellular junctions in MDCK cell monolayers (Figure 2A) 
and in modulating the intact MDCK cell monolayers (Figure 2B). Cyclic cHAVc3 was a 
derivative of cHAVc1 with deleted Ala6 and Ser7 residues; this deletion increased the 
backbone rigidity while reducing the size to a hexapeptide. It is interesting that cHAVc3 
has previously been investigated and not found to inhibit the N-cadherin-mediated cell 
adhesion process [36]. This suggests that cHAVc3 peptide is selective for E-cadherin 
over N-cadherin. Thus, the conformational rigidity of cyclic cHAVc3 peptide may 
contribute to its activity and selectivity for E-cadherin compared to HAV4 and cHAVc1.  
The BBB modulatory activities of cHAVc3 and HAV4 peptides were further 
compared in enhancing brain delivery of Gd-DTPA in Balb/c mice. The brain 
deposition of Gd-DTPA in mice was enhanced by both peptides in a concentration-
dependent manner (Figures 4 and 5). Cyclic cHAVc3 had significantly higher activity 
than HAV4 in enhancing the delivery of Gd-DTPA. In the posterior region, cHAVc3 
showed an eightfold enhancement of Gd-DTPA (Figure 4E) while HAV4 had only a 
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fivefold enhancement (Figures 4B). Increased activity of cHAVc3 was also supported by 
the AUC comparison of Gd-DTPA entry into the brain in the posterior region (Figure 
5C). Taken together, both in vitro and in vivo studies indicated that cyclic cHAVc3 
peptide had a greater ability to modulate the intercellular junctions than the linear 
HAV4 peptide.  
The MRI studies measuring the brain deposition of Gd-DTPA showed regional 
differences in BBB permeability with the posterior having the greatest accumulation, 
followed by the mid-brain and anterior regions. Although not assessable with many of 
the methods used to measure BBB permeability, regional differences in both capillary 
density and permeability exist [37]. Despite these regional differences in basal BBB 
permeability, the cadherin peptides were able to modulate BBB permeability in all 
regions examined.  These results were consistent with previous studies with other 
cadherin peptides such as HAV6 [25] and cyclic ADTC5 [26]. 
The dynamic range of BBB modulation with the cadherin peptides was evaluated 
with several different imaging agents. The effect of the cadherin peptides on BBB 
permeability was most evident for Gd-DTPA. As it is a hydrophilic compound of 
approximately 900 dalton size, there is limited BBB permeability of this agent under 
normal conditions. However, substantial increases (3-4-fold) in the brain delivery of 
Gd-DTPA were observed following both HAV4 and cHAVc3 treatments. While both 
cadherin peptides also increased the delivery of IRdye800cwPEG, an approximately 
30,000 dalton near-infrared fluorescence contrast agent, maximal increases were only 
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around twofold in magnitude. The BBB permeability of the near-infrared fluorescent P-
gp contrast agent R800 was not affected by either cadherin peptide.  As R800 BBB 
permeability is influenced by transcellular diffusion and active drug efflux transport 
processes, the impact of the cadherin peptides on brain delivery of R800 was expected 
to be minimal.     
The plasma stability of cHAVc3 was also better than that of HAV4 with t1/2 = 
12.95 h for cHAV3 and t1/2 = 2.4 h for HAV4. This result suggests that cHAVc3 is more 
stable in systemic circulation than HAV4 after i.v. administration. The structural 
rigidity of cyclic cHAVc3 suppressed its rate of proteolysis in the blood compared to 
linear HAV4 peptide [35, 38]. Previous studies have shown that peptide cyclization 
prevented proteolytic degradation in plasma and improved the half-life of the peptide 
in systemic circulation [39]. The longer residence time of cyclic cHAVc3 peptide in the 
systemic circulation compared to the linear HAV4 peptide could influence the 
magnitude and duration of BBB modulation observed with the peptides.  
The duration of BBB opening caused by both peptides was determined by 
measuring peptide response when given as a pretreatment. While both the linear and 
cyclic cadherin peptides were able to modulate BBB permeability, there were notable 
differences in the duration of BBB opening with the two peptides in terms of the size of 
delivered molecules. For Gd-DTPA, the small molecular weight paracellular marker, 
the duration of BBB modulation observed with HAV4 was less than 1 h (Figure 6).  In 
contrast, based on the MRI studies examining effects of various pretreatment times, 
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cHAVc3 had a window of BBB opening from 2–4 h (Figure 6).  These findings are 
similar to those of our previous studies with the cyclic cadherin peptide, ADTC5, in 
which BBB modulation was observed for 2 h, but was completely reversed by 4 h 
following treatment [26].  Such differences in duration of opening with the linear and 
cyclic cadherin peptides may be due to improved molecular interactions of the cyclic 
peptide with the extracellular domain of cadherin and/or improved plasma stability.   
Interestingly, studies with IRdye800cw-PEG, the large molecular weight 
paracellular marker, indicated restoration of BBB permeability within 1 h for both 
peptides (Figure 7). For applications involving delivery of larger therapeutic molecules, 
infusions of cadherin peptide may be required to insure an adequate duration of BBB 
modulation. However, for small molecule brain delivery applications, the relatively 
limited duration of BBB modulation to the larger molecular weight molecules could be 
an advantage as it would reduce plasma protein deposition into the brain, which is a 
major contributor to toxicity observed with other BBB disruption methods. Our 
hypothesis is that the cadherin peptide modulates the BBB to create large, medium, and 
small size pores in the intercellular junctions as soon as the peptide is administered. As 
time progress, the large pores immediately collapse to medium and small size pores 
and followed by the collapse of medium pores to small pores. Finally, it leads to the 
resealing of the intercellular junctions to a normal condition. In other words, the rate of 
large pores disappearance (collapse) is faster than the rates of the collapse of medium 
and small size pores in the intercellular junctions. This could be the possible reason of 
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why a large molecule such as IRdye800cw-PEG could not be delivered after 1 h peptide 
pretreatment while a small molecule such as Gd-DTPA could be delivered after 1 h 
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3.1 Introduction 
Brain diseases are difficult to treat because drug molecules cannot be easily 
transported from the bloodstream to the brain. The endothelial microvessels can 
deliver nutrients to the brain; however, these microvessels also comprise the blood-
brain barrier (BBB), which is a selective barricade that prevents unwanted 
molecules from entering the brain from the bloodstream. Many drug and diagnostic 
molecules cannot cross the BBB; therefore, there is a need to develop new methods 
for delivery of drugs and diagnostic molecules across the BBB to treat diseases of 
the central nervous system (CNS). Only a very few methods, such as using brain 
osmotic solutions, have been successful in improving brain delivery in a non-
invasive manner [1, 2]. In that approach, the hyperosmolarity of the osmotic 
solution used to deliver the drug modulates the intercellular junctions of the BBB 
by shrinking the vascular endothelial cells. Because the current choices are so 
limited, any new alternative and selective methods to deliver therapeutic and 
diagnostic molecules to the brain would help patients with brain diseases. Our 
group and others have developed peptides to enhance delivery of molecules to the 
brain by modulating protein-protein interactions (i.e., those of occludins, claudins, 
cadherins) in the intercellular junctions of the BBB [3, 4]. 
The HAV6 peptide (Ac-SHAVSS-NH2) derived originally from the first domain 
(EC1) of E-cadherin enhances the brain delivery of a paracellular marker molecule 
(i.e., 14C-mannitol) across in vitro cell culture monolayers of Madin-Darby canine 
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kidney cells (MDCK) [5]. The HAV6 peptide can also increase the brain delivery of 
14C-mannitol and 3H-dounamycin in the in-situ rat brain perfusion model as well as 
Gd-DTPA, R800 near IR (NIR) dye, and R800cw-polyethylene glycol (25 kDa) in 
Balb/c mice in vivo upon intravenous (i.v.) administration [6, 7]. Recently, the cyclic 
cHAVc3 peptide (cyclo-(1,6)Ac-CSHAVC-NH2) was shown to have better activity 
than linear HAV4 peptide (Ac-SHAVAS-NH2) in modulating the intercellular 
junctions of MDCK cell monolayers and in enhancing in vivo brain delivery of Gd-
DTPA in Balb/c mice. In addition, cyclic cHAVc3 has better plasma stability than 
the linear HAV4 peptide.  
The proposed hypothesis for the general mechanism of action of synthetic 
HAV peptides is that they modulate the BBB via binding to the EC repeat 
domain(s) of E-cadherin; as a result, the peptides disrupt cadherin-cadherin 
interactions in the intercellular junctions of the BBB. The disruption of cadherin 
interactions increases pore sizes in the intercellular junctions of the BBB and 
enhances the penetration of molecules through the BBB. Because the EC1 domain is 
known to be one of the most important repeat domains in cadherins, we have 
proposed that HAV peptides bind to the EC1 domain to modulate E-cadherin 
homophilic interactions [8-10]. The results from this study will provide guidance in 
designing better BBB modulators for improving delivery of molecules into the 
brain. 
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In this study, the binding properties of the cHAVc3 peptide to the EC1 
domain of human E-cadherin were evaluated using 1H,-15N-heteronuclear single 
quantum correlation (HSQC) NMR spectroscopy, molecular dynamics simulation, 
and molecular docking experiments [11, 12]. The amino acid assignments in the 
EC1 domain were completed previously using 3D NMR spectroscopy [13]. The EC1 
domain was titrated with the peptide, and the NMR chemical shift perturbations 
(CSP) for the affected residues were monitored to determine the peptide-binding 
site on the EC1 domain [11]. CSP has also been used to estimate the dissociation 
constant (Kd) of cHAVc3 to the EC1 domain [14].  The conformations of cHAVc3 
peptide and the EC1 domain were evaluated with molecular dynamics simulations, 
and the potential peptide-binding site was determined in molecular docking 
experiments using residues that were affected by the peptide titration.   
 
3.2 Materials and Methods 
3.2.1 Peptide Synthesis and Cyclization 
The linear precursor of cyclic cHAVc3 peptide was synthesized using a 
solid-phase method with Fmoc chemistry in a peptide synthesizer (Pioneer, 
PerSeptive Biosystems). The linear peptide was cleaved from the resin and purified 
by reversed-phase HPLC using a C18 column.  The cyclization reaction was done 
by bubbling air into a dilute solution of peptide in sodium bicarbonate buffer at pH 
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8.5 as previously described [15]. The peptide was purified with semi-preparative 
HPLC using a C18 column. Mass spectrometry was used to confirm the molecular 
weight of the cHAVc3 peptide [6].  
3.2.2 Protein Expression and Purification  
Expression and purification of the 15N-labeled EC1 domain protein with 138 
residues were accomplished using our previously published protocol [13]. The 
protein contains 110 residues from the EC1 domain and 28 residues at the C-
terminus from the sequence of the EC2 domain. The N-terminus was connected to 
Streptag I sequence (WSHPQFEK) via a Factor Xa sequence (IEGR) for affinity 
purification using a Strep Tactin II column with size 5.0 × 0.6 cm (GE Healthcare 
Life Sciences, Pittsburgh, PA). The cDNA of the 138 residues protein (BlueHeron, 
Bothell, WA) was subcloned into pASK-IBA6 plasmid (Genosys, Woodland, TX). 
The cDNA vector of 2 µL was added in sterile technique to 100 µL of BL21 cells for 
30 min in ice.  Then the mixture was placed in a water bath at 42°C for 30 s to allow 
cDNA to enter the cells; this was followed by 3 min in ice. 200 µL of SOC medium 
(1.55 g yeast, 0.25 mL of 1M KCL, 0.5 mL of 1 M MgCl2, 0.5 mL of 1 M MgSO4, 1 mL 
of 1 M glucose in ddH2O) was added to the mixture. The mixture was shaken at 250 
RPM and 37°C for 0.5–1 h. Two aliquots of the mixture (50 and 100 µL) were added 
to different agar plates followed by incubation for 12–16 h at 37°C. One or two 
colonies were selected from either a 50- or 100-µL-plate and added to 10–20 mL of 
LB medium (10 g NaCl, 10 g peptone, 5 g yeast up to 1 L of dd H2O). Ampicillin 
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solution (10–20 µL of 100 mg/mL) was added into the small-scale expression 
followed by overnight incubation at 37°C. The 20 mL LB medium was added to 1 L 
of 5× M9 medium (200 mL M9 minimal medium with 15N-NH4Cl as a nitrogen 
source, 2 mL of 1 M MgSO4, 10 mL of 40% glucose, 0.5 mL of 1 M CaCl2, 1 mL of 1% 
FeSO4, 1 mL of 1% thiamine, 1 mL of antibiotic 100 mg/mL) until the cells density 
was 0.6–0.8 at OD600 nm. Cell growth was induced using 50 µL anhydrotetracycline 
(2 mg/mL, Promega Inc., Madison, WI) to express the 15N-labeled EC1 followed by 
incubation for 6 h at 30°C. The resulting cells were harvested by centrifugation at 
10000–12000 RPM, and cell pellets were immediately stored at –80°C.  
Prior to the NMR experiment, the 15N-labeled EC1-containing cells were 
taken from the –80°C freezer and subjected to lysing by sonication (Sonic 
Dismemberator) for 10 s every min for 30 min at 65 Hz in binging (or B) buffer  (100 
mM Tris, 150 mM NaCl, 1 M EDTA, 1 mM DTT, 0.02% NaN3, pH 8). Then, the lysed 
cells were centrifuged at 14000 RPM for 1 h at 4°C. The supernatant was passed 
through a 0.2 µm sterile filter and concentrated by centrifugation using Amicon 
Ultra tubes (EMD Millipore, Billerica, MA) with 10,000 or 3,000 Da molecular 
weight cutoff. The concentrated 15N-labeled EC1 was purified using a StrepTactin II 
column. The column was equilibrated and washed with B buffer before and after 
protein solution exposure to the column at 5 mL/min flow rate. Pure protein was 
then eluted from the column by elution buffer (B buffer + 2.5 mM desthiobiotin) at 
a low flow rate of 2 mL/min. Tris-Bis SDS-PAGE (4–12%) was used to check the 
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purity of the protein fractions.  The protein was concentrated to 0.18–0.3 mM for 
NMR studies with Amicon Ultra tubes by centrifugation, and the protein 
concentration was monitored with a UV spectrophotometer at 280 nm using molar 
absorptivity of 19480 M-1 cm-1 [8]. The EC1 domain in elution buffer was dialyzed 
overnight with 20 mM phosphate buffer containing 5 mM DTT. Two hours before 
the NMR experiment, the DTT was removed from the EC1 buffer by dialysis using 
20 mM phosphate buffer or by centrifuging with Amicon Ultra tubes with 3,000 Da 
molecular weight cutoff for 15–20 min. DTT was removed to prevent reduction of 
the disulfide bond in the cyclic cHAVc3 peptide during the titration procedure.   
3.2.3 NMR Experiments for Titration of EC1 with cHAVc3 Peptide 
Two-dimensional (2D) 1H,-15N-HSQC NMR experiments were carried out 
using a Bruker Avance 800 MHz NMR spectrometer (Billerica, MA) equipped with 
TCI cryoprobes. The effects of titration of cHAVc3 peptide on the 15N-labeled EC1-
domain were evaluated in buffer containing 10% D2O. The HSQC NMR spectra 
were acquired with 10 or 16 scans, depending on the EC1 domain concentration. 
The peptide-to-protein ratios (cHAVc3: EC1) were from 0.3:1.0 to 2.5:1.0 for the low 
range and from 1:1 to 10:1 for the high range. The lower range titration ratios were 
used to estimate the Kd values of cHAVc3 peptide. For each titration point, 10 µL of 
cHAVc3 peptide was added to a sample of 500 µL of EC1. Then the data for each 
titration point were processed using NMRPipe program (nmrDraw and 
view2D.tcl). The chemical shift perturbation (CSP) and broadening of the 1H or 15N 
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peaks from the EC1 residues were used to determine the potential binding site and 
the dissociation constant (Kd) of the cHAVc3 peptide.  The CSP was calculated 
using the following equations [16] : 
ΔF = [(Δδ1H* (800.234 Hz/ppm))2 + (Δδ15N* (81.096 Hz/ppm))2]1/2 (1), 
where ΔF represents fraction bound of protein and Δδ1H or Δδ15N represents the 
difference between free and bound protein for the EC1 domain for each NMR 
nucleus. Then, ΔF was plotted against the peptide concentration, and the Kd was 
calculated using non-linear regression for best fitting [14]: 
Δobs = Δmax ((Po + Kd + Lo) –[(Po + Kd + Lo)2 – 4 PoLo]1/2)/2 Po,  (2),   
where Δobs is the difference between bound and free protein, Δmax is the 
penultimate titration, and Po and Lo are total EC1 concentration and total cHAVc3 
concentration, respectively. 
3.2.4 Molecular Dynamic Simulations  
3.2.4.1 MD Simulation of the EC1 Domain  
Molecular dynamics (MD) simulations were carried out to evaluate the 
dynamic movements of the EC1 domain and its C-terminal tail region. The X-ray 
structure of the EC1 domain (PDB file 2O72 from the Protein Data Bank) was used 
as the starting structure [17]. The EC1 structure was solvated in a cubic box of 35307 
TIP3P water of size 10.27578 nm. To simulate the ionic strength to 0.15 M, 86 Cl- and 
98 Na+ ions were added by replacing water molecules. Ionization states of titratable 
 89  
residues were assigned corresponding to pH 7.0 conditions. After energy 
minimization, a brief constrained MD simulation and 100 ps unconstrained 
equilibration of EC1 were done. The EC1 structure was then subjected to an 
unconstrained MD simulation for 100 ns at a constant temperature of 300 K. The 
final structure from the MD simulations was used as a model for the solution 
structure of the EC1 domain and for molecular docking simulations with cHAVc3 
peptide. The simulations were done using GROMACS 4.6 program [18, 19] with the 
CHARMM27 force field and nonbonded interactions. The long-range electrostatic 
interaction was computed by PME (not cutoff) with a distance of 1.3 nm for short-
range non-bonded cutoff. The temperature of 300 K was maintained by the v-
rescale method. 
3.2.4.2 Replica Exchange Molecular Dynamic (REMD) Simulations for Linear HAVc3 
and Cyclic cHAVc3  
3.2.4.2.1 Simulation of the Linear HAVc3 Peptide as the Precursor of Cyclic cHAVc3   
The linear HAVc3 peptide (Ac-CSHAVC-NH2) was built using the 
CHARMM program [20] with acetylated N-terminus and amidated C-terminus. 
Both linear HAVc3 peptide without a disulfide bond and cyclic cHAVc3 peptide 
(cyclo(1,6)Ac-CSHAVC-NH2) with a disulfide bond were simulated in a box of 
water (TIP3P) with eight ions (4 ions each for Cl- and Na+). REMD simulations were 
performed for HAVc3 with 15 replicas in a temperature range of 320–480 K over 50 
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ns.  The rate for exchange attempts between neighboring replicas was every 1 ps; 
the observed exchange probabilities were in a range of 0.07–0.23 with cubic box size 
of 3.55578 nm and 1447 TIP3P waters. A GROMACS 4.5.6 program was used to 
simulate the peptide with CHARMM27 force field and non-bonded interactions as 
in the modeling of EC1. The structures sampled in the 320 K REMD were used to 
generate the cyclic peptide structure as described below. 
3.2.4.2.2 Simulation of Cyclic cHAVc3 
To allow HAVc3 peptide cyclization, a brief constrained MD was done for 
HAVc3 peptide structures from REMD simulations to bring two sulfur atoms to a 
distance of <2 Å. After forming a disulfide bond to make cyclic cHAVc3, a 50 ns 
REMD simulation was performed with conditions analogous to those of linear 
HAVc3 (see above), and exchange probabilities in the range of 0.1–0.18 were 
observed. Clustering was performed from the 5000 conformations sampled in the 
320 K replica trajectory of cHAVc3 using GROMOS algorithm [21]. The central 
structures from the five most populated clusters were selected to represent 95% of 
all sampled structures, and these structures were used for docking experiments 
with the EC1 domain of E-cadherin.  
3.2.5 Docking of cHAVc3 to the EC1 Domain using HADDOCK 
The coordinates for the human EC1 domain model were extracted from the 
final structure in the 100 ns EC1 MD simulation. Coordinates for five representative 
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structures of cHAVc3 from REMD simulations were used for the docking 
experiments. They were docked to the EC1 domain structure from the 100 ns EC1 
structure using HADDOCK server with the Easy Interface option. Both blind and 
NMR-constraints docking experiments were performed. The blind docking was 
carried out using all 138 residues of the EC1 as the potential binding site, while 
NMR-constraints docking experiments were done using the C9, Y36, I38, T63, F77, 
S78, I94, D103, and V112 residues as constraints for the potential binding site(s). The 
NMR constraint residues were selected from the chemical shift perturbation data of 
peptide titration experiments, and the HADDOCK clusters of docking were 
selected based on the highest HADDOCK scores [22, 23]. 
 
3.3 Results 
3.3.1 NMR Studies  
3.3.1.1 Determination of the Binding Properties of cHAVc3 on the EC1 Domain  
To identify the EC1 residues that showed CSP changes (i.e., interactions) 
when titrated with cHAVc3, the NMRPipe program was used to overlay the 2D 
1H,-15N-HSQC NMR spectrum of the free and peptide-titrated EC1 domain (Figure 
1). The peptide titration generated different magnitudes of CSP on the EC1 domain, 
including C9, N12, L21, Y36, S37, I38, I52, I53, T63, R68, F77, S78, H79, S82, S83, I94, 
D103, T109, V112, and F113 residues (Figure 1). These residues were selected based 
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on noticeable changes upon overlaying the NH crosspeaks of the free and titrated 
EC1 domain. The EC1 residues that have ΔF values higher than the total average 
ΔF value are considered to be residues that are involved in direct interactions with 
the peptide.  The residues that had ΔF values higher than the total average ΔF were 
C9, Y36, I38, T63, F77, S78, I94, D103, and V112. The residues that had ΔF values 
lower than the total average were N12, L21, S37, I52, I53, R68, H79, S82, S83, T109, 
and F113, and these were considered to be insignificant changes. These residues 
were assumed not to be involved in direct binding, and the chemical shift changes 
(or CSP) were due to conformational changes in the EC1 domain away from the 








































































































































 94  
 
Figure 1. The chemical shift changes of residues in the 2D 1H,-15N-HSQC NMR 
spectra of the free and peptide-titrated EC1 domain collected using Bruker Avance 
800 MHz spectrometer. (A) The overlay of partial 2D NMR spectrum of the EC1 
domain (red) and titrated EC-1 domain at the highest peptide concentration (black). 
(B) The overlay of crosspeak shifts from the NH of Ser78 (S78, left) and Asp103 
(D103, right) upon titration with cHAVc3 peptide from 0.3:1 to 2.5:1 peptide-to-
protein molar ratios. (C) The observed chemical shift perturbation (CSP) of the EC1 
residues weighted for both 1H, and 15N using equation 1 when titrated with 
cHAVc3 peptide at a peptide/protein ratio of 2.5:1. (D) The 15N chemical shift 














































































































 95  
 
3.3.1.2 Determination of Dissociation Constant (Kd) of cHAVc3 to the EC1 domain 
The dissociation constant (Kd) of cHAVc3 peptide to the EC1 domain was 
determined using NMR data from the peptide titration experiments at the peptide-
to-protein ratios of 0.3:1 to 2.5:1. The estimated Kd values were determined using 
Δobs and Δmax using equation 2 on different residues (i.e., C9, R68, F77, S78, I94, 
D103, and V112) with ΔF values (Equation 1) as represented by the F77, S78, and 
V112 residues in Figure 2. The Kd values of the R68 and I94 residues were measured 
using only the chemical shift changes in 15N nucleus: Δδ15N = δ15Nobs – δ15Nfree.  The 
calculated Kd values from various residues ranged from 0.5 × 10-5 to 7.0 × 10-5 M 
(Table 1).  
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Figure 2. The 1H,-15N-weighted CSP changes (ΔF) from the NMR spectrum as a 
function of peptide/protein ratios for representative residues in the EC1 
domain: (A) S78, (B) V112, and (C) F77. The Kd was estimated using nonlinear 
regression for the simulated curve (-.-.-). The saturation point was estimated 
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Table 1. The estimated Kd values of binding between cHAVc3 and 
the EC1 domain of E-cadherin determined using 1H,-15N CSP of 
different residues upon peptide titration with cHAVc3:EC1 ratios 
of 0.3:1 to 2.5:1. 










3.3.3 Molecular Modeling Studies of Binding between cHAVc3 and the EC1 domain  
3.3.3.1 Molecular Dynamics for the EC1 domain 
To evaluate the dynamic properties of the EC1 domain used in the NMR 
studies, the starting structure had 138 amino acid residues that are derived from the 
sequence of the EC1 domain (110 residues as the “head region”) plus 28 residues 
from the EC2 domain sequence of the “tail region.” Because the starting structure 
was derived from the X-ray structure of the EC1-EC2 domains of human E-
cadherin, the tail region extended away from the head EC1 domain (Figure 3A). At 
100 ns MD simulations, the tail region moved closer to and interacted with the head 
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region (EC1, Figure 3B). The movement of the tail group was due to the absence of 
crystal packing in the starting X-ray structure. The starting structure and the final 
MD structure were overlaid using the C-alpha of the backbone residues 1 to 90. 
This comparison showed a root-mean-square-deviation  (RMSD) of 0.746 Å (Figure 
3C), indicating a stable head region. This study suggests that the EC1 structure in 
solution has the head region retained in its folded structure while the flexible tail 
region moves closer to the head region. 
 
 
Figure 3.  The comparison between (A) the starting structure, taken from the X-ray 
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final structure after 100 ns molecular dynamics simulations. (C) The overlay of the 
starting structure (magenta) and the final structure from MD simulations (pink). The 
structure from the MD simulations shows the C-terminal tail that swings into the main 
region of the EC1 domain as indicated by the curved arrow. After MD simulations, the 
alignment of the residues 1 to 90 between the X-ray structure and the MS simulation 
structure has RMSD < 1.0 and the tail is close to the head part of the protein. 
 
 
3.3.3.2 Molecular Dynamics of cHAVc3 
For docking studies, the structure of cyclic cHAVc3 was generated using 
CHARMM from the structure of linear HAVc3, which was subjected to 100 ps 
REMD simulations in a box of water molecules. The resulting structures of linear 
HAVc3 have an RMSD of 0.1Å, which was close to that of the initial structure.  
Then, a 50 ns REMD was carried out on linear HAVc3 with increasing constraints to 
pull the two sulfur atoms of the Cys residues to a distance of less than 0.2 nm. A 
disulfide bond was formed between two sulfur atoms of the cysteine residues of 
linear HAVc3 to make the cyclic cHAVc3 structure, followed by energy 
minimization. The cyclic cHAVc3 structure was then subjected to 100 ps REMD 
simulations to give acceptable probability exchange. A 50 ns REMD simulation at 
320 K was carried out to provide the top five structural clusters, and the central 
conformer from each cluster was used to represent each cluster (Figure 4).  The phi 
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and psi angles of each residue are shown in Table 1. The structures in both clusters 
1 and 2 contain type-I and type-VII β-turns, respectively, at His3-Ala4-Val5-Cys6, 
with a potential hydrogen bond from the NH of Cys6 to the C=O of His3. The 
structures in clusters 3 and 5 have type-I and type-I' β-turns, respectively, at Cys1-
Ser2-His3-Ala4, with a potential hydrogen bond from the NH of Ala4 to the C=O of 
Cys1. Finally, cluster 4 has structures with a γ-turn at Ala4-Val5-Cys6 with a 
potential hydrogen bond from the NH of Cys6 to the C=O of Ala4. 
 
 
Figure 4. The results from MD simulations to generate stable cyclic structures of 
cHAVc3 peptide. There are five different clusters of structures of cyclic cHAVc3 (A to 
A B C 
D E 
Figure'4'
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E). Conformation A has the highest number of structures in a cluster, suggesting that it 
is the closest to the solution conformation of cHAVc3. Conformation A was used for 
docking experiments with the EC1 structure for the MD simulation. Other conformers 
(B–E) were also used for molecular docking with the EC1 domain, and they gave 
docking results on the EC1 domain similar to those of conformation A. 
 
 
3.3.4 Molecular Docking of cHAVc3 to the EC1 Domain 
The purpose of the docking studies was to propose a working model of 
binding between the cHAVc3 peptide and the EC1 domain. The potential binding 
site(s) was searched with the help of experimental data from peptide titration 
observed by 2D-NMR. The NMR-constraints docking experiment showed that the 
cHAVc3 structures with the highest HADDOCK scores were clustered around the 
F77 and S78 residues on the EC1 domain. This suggests that the region around F77 
and S78 residues is the potential binding site for cyclic cHAVc3 peptide (Figure 5). 
The second highest docking score was found in a cluster of molecules that were 
docked on the tail region around the V112 residue. Finally, the third highest 
docking score was in a cluster of molecules that docked on the region around the 
K105 and D103 residues. The NMR data from titration experiments showed that the 
highest ΔF value was from the residue S78, supporting the suggestion that the 
potential binding site of cHAVc3 is around the S78 and F77 residues (Figure 5). The 
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detailed interaction between cHAVc3 on the EC1 around both F77 and S78 is shown 
in Figure 5, where hydrophobic pockets bind to the Ala and the disulfide bond of 
the cHAVc3 peptide, respectively. For the blind docking experiments, the highest 
scoring clusters were found around the K105/D103 residues. Finally, the third 
cluster was found around the V112 residue region (supplementary). 
 
Figure'5A'
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Figure'5B'
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Figure 5.  (A) The docking model of conformation A of cHAVc3 to the EC1 domain 
(black arrow) to indicate the potential binding site of cHAVc3 peptide in EC1. (B) The 
interaction region of cHAVc3 (blue) on the residues of EC1 (cyan). The S78 residue has a 
hydrophobic pocket that interacts with the Ala4 residue of cHAVc3 peptide. The F77 
residue has the same type of interaction with the disulfide bond of the peptide. (C) The 
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3.4 Discussion 
The NMR assignments of amino acids in the EC1 domain of human E-
cadherin (h-E-cadherin) were done using the 15N-labeled and 13C/15N-labeled EC1 
domain [13]. These assignments were accomplished with the help of the NMR 
assignments of the EC1 domain of mouse E-cadherin [13, 24]. The difference 
between the human EC1 (h-EC1) domain studied here and the mouse EC1 (m-EC1) 
domain is that the h-EC1 domain has an additional 28 amino acid residues from the 
EC2 domain at the C-terminal, which is called the tail region. The function of the 
tail region is to stabilize the conformation of the h-EC1 domain. Although the CD 
spectrum of the h-EC1 domain without the tail region showed a folded structure 
with a high beta-sheet secondary structure [25, 26], the NMR spectrum of the EC1 
domain did not show well-spread crosspeaks in the HSQC spectrum. This suggests 
that without this tail region the structure of the EC1 domain is folded but rather 
dynamic in nature. Many attempts to change the solution conditions (i.e., pH, ionic 
strengths, various buffers) to stabilize the EC1 domain without the tail region for 
NMR study were not successful [25, 26]. In contrast, the m-EC1 domain has a stable 
conformation in solution and produces well-spread crosspeaks in the NMR 
spectrum for structural determination [24]. 
Here, MD simulations were done to observe the dynamic behavior of the 
EC1 molecule, especially the role of the tail region in stabilizing the structure of 
EC1. The starting structure of the EC1 domain was from the X-ray structure of h-E-
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cadherin with the extended tail region derived from the sequence of the EC2 
domain and without interaction with the head region. Because the NMR data 
showed that the tail region was important in stabilizing the solution structure of the 
head region of EC1, molecular dynamic simulations were carried out in an explicit 
water environment. The results showed that the tail region swings into and 
interacts with the head region of EC1 as indicated by the dramatic changes of the 
RMSD of the tail residues (Figure 3C). This indicates that these interactions stabilize 
the structure of the EC1 domain in solution. After MD simulations, the RMSD was 
determined using alignments of C-alpha backbone from residues 1–90 for EC1 from 
MD simulation and X-ray as well as m-EC1 from the NMR study (Figure 3C). The 
results show a small magnitude of the RMSD, indicating that there is limited 
change in the head region of the h-EC1 domain during MD simulations. The 
majority of the change occurred in the tail region that swung closer to and 
interacted with the head region of EC1.  
The structure of the EC1 domain from MD simulations was used to 
determine the binding site of cHAVc3 by implementing the NMR constraints from 
the CSP data upon peptide titration. The observed CSP could also be the result of 
local conformational changes in the EC1 as a consequence of peptide binding [12, 
27, 28]. Although the magnitude of CSP varied from residue to residue, the residues 
that have CSP values higher than average are C9, Y36, I38, T63, F77, S78, I94, D103, 
and V112. The high CSP changes were attributed to binding to the EC1 domain, 
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and these were used as NMR-constraints in the docking experiments to search for 
binding site(s) of the peptide [27]. The docking model shows that the cHAVc3 
peptide interacts with residues Y36, I38, F77, S78, and I94 with CSP values higher 
than average, as well as with S37, I53, and H79 with CSP values lower than average 
(Figure 7). This binding site has high consistency with the NMR data (Figure 1C).  
Free docking calculations yielded several possible models for cHAVc3:EC1 
complexes. However, the availability of NMR CSP data allowed generation of more 
reliable microscopic models by docking with NMR-constraints. 
There are also residues with low and high CSP values that are far away from 
the binding site; these residues include D103, T109, V112, and F113 (Figure 7). The 
observed CSPs in these residues were attributed to conformational changes on the 
tail region of EC1 during peptide binding. It is interesting to find that the large 
change in chemical shift of D103 can be attributed to the conformational swing of 
the tail region to stabilize its interaction with the head region (i.e., EC1) (Figure 3C). 
The D103 residue can be categorized as the hinge residue for the dynamic 
movement of the tail region to interact with the head region. The dihedral angle 
measurement (ϕ; ψ) of D103 from 0 ns (X-ray structure) to 100 ns (MD structure) 
showed that the ψ of D103 changed dramatically (Figure 6). In the other hand, the ψ 
measurements of D100 and N104, flanking residues around D103, did not change 
dramatically during the MD run (Figure 6). This suggests that the D103 residue 
behaves as a hinge residue to move the tail region closer to the head region of EC1 
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(Figure 3C). In addition, the CSP comparison among the S78, D103, and V122 
residues at the initial titration points shows that the CSP values of the D103 and 
V112 residues are less sensitive than that of S78 when titrated with the peptide, 
suggesting that cHAVc3 more likely binds to the region of the S78 residue.  T109, 
V112, and F113 from the tail region were additional residues that were affected by 
peptide titration (Figure 7); these residues from the tail region are clearly 
interacting with the head region of the protein. The observed CSP values in the tail 
region are due to the conformational changes in the tail region upon peptide 
binding. This result also supports the idea that the tail region folded into the head 
region of EC1 as indicated by the MD simulation results. 
The Kd values were estimated by curve fitting simulations using NMR data 
of chemical shift changes from several residues (i.e., C9, F77, S78, I94, D103, and 
V112) at different peptide:protein ratios (<2.5:1.0). The low range Kds of cHAVc3 
binding to EC1 were estimated to be around 0.5 × 10-5 – 1.0 × 10-5 M using the F77, 
C9, R68, and D103 residues (Table 1). The medium range Kd was estimated using 
the S78 residue, and the high range Kds were estimated from the V112 and I94 
residues.  For the R68 and I94 residues, the chemical shift changes in 15N as [PL] 
complex (Δδ15N; 1D) was fitted in the titration curve.  
The calcium-binding region in E-cadherin was found at the interface 
between the EC1 and EC2 domains, and the D103 and the tail region of EC1 studied 
here contained part of the calcium-binding site. It has been shown previously that 
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cadherin molecules form a rod-like structure (or extended structure) due to the 
coordination of calcium at the interface region. In the absence of calcium, the rod-
like structure collapses into a globular cadherin structure. In this study, the tail 
region swinging to interact with the head region of EC1 could be a natural behavior 
of this protein in the absence of calcium, and it is reasonable to speculate that the 
D103 residue is also involved in the dynamic conversion of a rod-like structure in 
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Figure 6.  (A) The changes in psi (ψ) angle of D103 (u), D100 (n) and N104 (p) residues 
during the molecular dynamics run of EC1 domain in water.  Comparing to the ψD103 in 
the X-ray structure (0 ns) shows dramatic changes during the MD run. The ψ angles of 
D100 and N104 (flanking residues of D103) showed no dramatic changes between the 
X-ray and MD structures in comparison to ψD103. (B) The changes in phi (Φ) angles of 
D103 (u), D100 (n) and N104 (p) residues in which ΦD103, ΦD100 and ΦN104 experienced 
similar changes during the MD run. (C) The RMSD per residues between the X-ray and 
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Figure 7. The MD structure of the EC1 domain showing residues that had higher ΔF 
values (red) and residues with lower ΔF values (yellow) when the EC1 domain was 
titrated with cHAVc3 peptide. The pocket for cHAVc3 peptide in EC1 domain is 
represented by S78, F77, H79, Y36, S37, and I38, along with the surrounding I94 and I53 
residues.  Most chemical shift changes (red and yellow colors) are closed to the binding 
pocket of cHAVc3, indicating the binding region of cHAVc3 peptide. The chemical shift 
changes of the tail residues, including the D103 residue, can be attributed to the 
dramatic conformational changes of the tail region. 
Figure'7'
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Table 2. The phi and psi angles for amino acid residues of cHAVc3 peptide in 
different stable clusters of conformers from MD simulations. Secondary 










  Cys1 Ser2 His3 Ala 4 Val5 Cys6 
Cluster 1 
phi –106.1 –108.5 –121.9 –63.5 –95.1 –124.9 βI-turn at 
H3-C6 
psi 144.2 139.0 –6.5 –39.9 –58.1  84.2 
Cluster 2 




turn at C6 psi 137.2 3.9 160.5 –41.3 126.7 77.4 
Cluster 3 
phi –116.3 –70.8 –107.5 –77.3 –108.3 –104.5 βI-turn at 
C1-A4 psi 21.4 –41.5 –27.8 162.3 110.2 74.1 
Cluster 4 
phi –68.1 68.0 –145.9 –59.3 72.1 –67.6 γ-turn at 
V5 
psi –36.2 43.3 169.3 –34.4 –47.3 –19.0 
Cluster 5 
phi –112.9 61.1 60.8 –141.5 –52.1 –84.9 βI'-turn at 
C1-A4 psi 14.4 48.1 28.5 164.3 146.7 –7.3 
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4.1 Introduction 
The intercellular junctions of the blood-brain barrier (BBB) are mediated by 
protein-protein interactions form apposing cell membranes. The adheren junction 
of the BBB is partly mediated by calcium dependent cadherin-cadherin interactions 
(i.e., E- and VE-cadherins) and calcium independent Nectin interactions [1]. The 
primary structure cadherin include a C-terminal cytoplasmic domain, a single 
transmembrane domain, and an extracellular (EC) N-terminal domain. The EC 
domain composed of five repeat domains, which are designated as EC1, EC2, EC3, 
EC4, and EC5 domains. Three calcium ions with different Kds bind at the interface 
between two EC domains (between EC1 and EC2) [2]. These calcium ions are 
responsible to maintain the rod-like structure of the entire EC domain and the EC 
domain will fold to form a globular structure in the absence of calcium ions [2].  
The mechanisms of cadherin-cadherin interactions have been studied using 
various methods, including using cell-adhesion assays and structural studies with 
X-ray crystallography and NMR spectroscopy using intact and truncated EC 
domains of cadherins. The similarity in EC domains of classical cadherin was 
shown using NMR, X-ray, and site-mutagenesis assays [3]. To form cell-cell 
adhesion at the intercellular junctions of biological barriers, several mechanisms of 
cadherin interactions have been proposed [4]. One proposed mechanism involves a 
homophilic interaction (trans-interaction) between EC1 domains form two apposite 
cell membranes (i.e., EC1-to-EC1 interaction) [5-7]. A second mechanism is called a 
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“zipper model” in which a cis-interacting dimer of two EC1 domains from one cell 
membrane forms a trans-interaction with another cis- dimer of EC1 domains from 
the opposing cell membrane. The trans-interaction involves domain swapping of 
the N-terminal of EC1 to a hydrophobic pocket of the opposing EC1 domain [4, 8].  
The X-ray structure of C-cadherin shows a domain swapping mechanism of the 
EC1 domain in trans-interaction as well as a cis-interaction between EC1 of one 
cadherin molecule to EC2 of a parallel neighboring molecule [9]. The involvement 
of all five EC domains to form strong intercellular of E-cadherin has also been 
proposed after studying E-cadherin with truncated domain(s) using cell adhesion 
assays [6, 10, 11]. The C-terminal intracellular region of E-cadherin interacts with to 
β-catenin that binds to F-actin cytoskeleton complex via α-catenin. The monomeric 
α-catenin is essential to bind to β-catenin and then to cytoplasmic domain of E-
cadherin; the dimeric form of α-catenin cannot bind to β-catenin. The cytoplasmic 
domain of E-cadherin also binds to p120ctn that is essential for E-cadherin function 
[6].   
Previously, ADT and HAV peptides (Table 1) from the EC1 domain of 
human E-cadherin (hE-cadherin) have been shown to modulate the intercellular 
junctions of Madin-Darby Canine Kidney (MDCK) cell monolayers and enhance 
paracelluar transport of 14C-mannitol across the cell monolayers [12, 13]. HAV6 
peptide (Ac-SHAVSS-NH2) enhanced transport of fluorescence-labeled dextran 
(MW = 4,400 Da) across the bovine brain microvessel endothelial cell (BBMEC) cell 
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monolayers [14]. Recently, linear and cyclic HAV (i.e., HAV6, HAV4, cHAVc3) and 
ADT (i.e., ADTC5) peptides were shown to increase the brain delivery of various 
molecules including paracellular markers (i.e., 14C-mannitol, R800-cw-PEG 25 kDa), 
magnetic resonance imaging (MRI) contrast agent (Gadopentic acid or Gd-DTPA), 
near IR (NIR) dyes (R800) and anticancer drug (3H-daunomycin) using in-situ rat 
brain perfusion model as well as in vivo Balb/c mouse model [15-18]. It is proposed 
that the mechanism of activity of HAV and ADT peptides is via binding to the EC1 
domain of E-cadherin to inhibit cadherin-cadherin interactions and increase the 
pore size of paracellular pathway of the BBB.  
In this study, the binding properties of HAV6, ADTC5, ADTC7, ADTC9 
peptides to the EC1 domain of hE-cadherin were investigated using NMR data and 
molecular docking simulations. The 15N-labeled EC1 domain was titrated with each 
peptide and the chemical shift perturbations (CSP) in the spectra of 1H,-15N-
heteronuclear single quantum correlation (HSQC) NMR experiments were 
monitored for each residue of the EC1 domain. The docking experiments were 
conducted using NMR data constraints to determine the potential binding site of 
each peptide on the EC1 domain. The CSP values from NMR data of peptide 
titration experiments were used to estimate the dissociation constant (Kd) of each 
peptide to the EC1 domain. 
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4.2 Material and Methods  
4.2.1 Dynamic Structure of EC1 Domain 
The structure of EC1 domain used here was obtained from molecular 
dynamic (MD) simulations in a box of water using the X-ray structure of free EC1 
domain (PDB code; 2O72) as the starting structure [19]. The studied EC1 domain 
has a total of 138 amino acid residues, which includes a flexible tail of 28 residues 
from the EC2 domain. The entire MD structure of EC1 at 100 ns was then compared 
to the standard X-ray structure from which a small RMSD value of 0.781 was 
obtained as described previously [20] .  
4.2.2 Cadherin Peptide Structures 
The PDB files of ADTc5, ADTc7, ADTc9 and HAV6 cadherin peptides were 
obtained using InsightII Program and their energy minimizations performed using 
CVFF91 force field (Accelrys, Inc. San Diego, CA) [21, 22] .  
4.2.3 NMR-Constrained Docking Experiments  
ADT and HAV peptides were docked onto the EC1 structure from MD 
simulations using HADDOCK program with Easy Interface option. The “active 
amino acids residues” of EC1 were selected based on chemical shift perturbation 
(CSP) analysis of NMR data for ADTc5, ADTc7, ADTc9 or HAV6 peptides [21, 22]. 
Residues of EC1 that showed noticeable chemical shift changes upon titration 
ADTc5, ADTc7, ADTc9, or HAV6 peptides to EC1 domain were selected as “active” 
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residues. Active residues were submitted as NMR constraints to HADDOCK 
program as docking simulations.  
For ADTc5 peptide, the submitted active residues on the EC1 domain were 
selected from residues with large CSP values such as the I4, Y36, G58, R68, V98, 
T97, D103, and F113 residues. The active residues used for docking of ADTc9 were 
I4, L21, V48, I53, T97, V98, D103, F113, G115, E119 and T133 residues. For ADTc7 
peptide, the active residues used for docking experiments were similar to those in 
ADTc9 titration with addition of the I38 residue. For the HAV6 peptide, the 
submitted active residues on the EC1 domain were S78, V48, T98, I53, and D103. 
After docking experiment for each peptide (i.e., ADTc5, ADTc7, ADTc9, and 
HAV6), the top three highest scoring clusters were selected and analyzed as 
working models for peptide binding. 
4.2.4 Blind Docking Experiments  
To validate the NMR-constrained docking experiments, “blind docking” 
experiments were performed. In this simulation, all 138 residues of the EC1 domain 
were considered active and submitted to HADDOCK. As in previous simulations, 
the top three HADDOCK-scoring clusters were selected and analyzed. 
4.2.6 Structural Analysis of Docking Clusters 
Each cluster file (PDB file) revealed interactions between EC1 domain and 
the peptide. LigPlus program was used to view the two-dimensional diagram of 
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interactions between the EC1 domain and each peptide as reported by HADDOCK. 
PyMOL program (PyMOL Molecular Graphics System, Version 1.3, Schrödinger, 
LLC.) was used for plotting and visualizing the interactions in 3D [23, 24]. 
4.3 Results  
4.3.1 Binding Characteristics of ADTc5 Peptide to the EC1 Domain:  
There were eight cluster models found during the docking experiment of 
ADTc5 peptide and all but one cluster models were approximately in close 
proximity to each other (Table 2). Clusters #5 and #8 have the top-two high 
HADDOCK scores and these clusters were used to represent binding characteristics 
of ADTc5 peptide to the EC1 domain (Figure 1A). In cluster #5, ADTc5 interacts 
with the following residues: P6, S8, S9, T97, T99, P10, D100, Q101, D103, and K105; 
while in cluster #8, it interacts with the following residues: P6, S8, P10, T99, D103, 
and K105 (Table 2). Thus, the P6, S8, P10, T99, D103 and K105 residues were the 
common residues in both clusters #5 and #8  (Figure 2A). The NMR data from 
peptide titration indicated that the T97, V98, and D103 residues had the high CSP 
values, which were consistent with the seven clusters found in docking experiment. 
Cluster #6 was located in a different region from the other seven clusters, which 
might not be a favorable binding site. The Kd values of ADTc5 (Table 3) were 
estimated using titration curves with high and saturable CSP values of EC1 
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residues (Figure 3A). The I24, I53, G58, G115, E119, and T133 residues have Kd 
values around 9–47 μM (Table 3). 
4.3.2 Binding Characteristics of ADTc7 Peptide to the EC1 Domain:  
Docking experiments of ADTc7 on the EC1 domain produced seven cluster 
models and all except one of the cluster models were approximately close regions 
except one model (Table 2). The top two clusters with high HADDOCK scores 
(cluster #1 and cluster #7) were used to represent the six cluster models of ADTc7 
peptide. Both clusters bind to the N20, L21, and K105 residues on the EC1 domain, 
suggesting these residues defined the binding pocket for ADTc7 (Figure 1B). For 
cluster #1, ADTc7 interacts with residues E13, K19, N20, L21, K105, P106, G124, 
S126, and T125 in the EC1 domain. Similarly for cluster #7, the peptide interacts 
with residues I4, P5, I7, S8, P10, N20, L21, V22, Q23, W59, and K105 on the EC1 
domain (Figure 2B). The I4 and L21 residues in EC1 showed considerable high CSP 
values in the NMR data upon titration with ADTc7. Finally, cluster#6 represents 
the docking of ADTc7 to the tail region of the EC1 domain. It has been shown 
previously that the tail region moved upon titration with cadherin peptides, which 
was also reflected by the change in CSP values. The accepted titration curves for the 
EC1 residues (Figure 3B) that involved in the binding site of ADTc7 peptide to EC1 
were used to report Kd values (Table 3). The estimated Kd values using residues 
V98, I4, and T97 were 10, 10, and 22 µM, respectively (Table 3). 
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4.3.3 Binding Characteristics of ADTc9 Peptide to the EC1 Domain:  
The results from docking of ADTc9 peptide to the EC1 domain produced six 
clusters and all the clusters were found located close to each other on EC1 domain 
(Table 2). The two cluster models with the top HADDOCK scores were cluster #1 
and cluster #2; these clusters were used to represent the docking regions for ADTc9 
peptide (Figure 1C). The residues on the EC1 domain that involved in binding or 
the binding pocket for both cluster models were at the S9, P10, E13, N20, L21, K105, 
P106, T125, G124, S126 residues (Figure 2C). In cluster #1 docking model, the 
residues of EC1 that interact with ADTc9 peptide are S9, P10, E13, K19, N20, L21, 
K105, P106, G124, T125, and S126 (Figure 2C). In parallel, the residues that interact 
with the EC1 domain in cluster #2 are residues S9, P10, E13, P16, N20, L21, W59, 
K105, F108, P106, G124, T125, and S126. Titration of EC1 with ADTc9 peptide 
generated considerable CSP on the NMR spectrum of L21 and this residue also 
interacted with the peptide in both cluster #1 and #2 models. The CSPs from 
several EC1 residues were followed during the titration and the titration curves 
from these residues were used to estimate the Kd values of ADTc9 to EC1 (Figure 
3C). The result from the titration curve of L21 has Kd of 190 µM while the titration 
curve results form I53 and V98 gave Kds of 403 μM and 480 μM, respectively (Table 
3). Overall, the Kd values of ADTc9 peptide were between 190 to 500 μM, indicating 
a weak-binding property of ADTc9 peptide to EC1.  
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4.3.4 Binding Characteristics of HAV6 Peptide to the EC1 Domain:  
There were a total of four clusters found in docking of HAV6 peptide to EC1 
domain (Table 2). Cluster #1 (Figure 1D) and cluster #3 (Figure 1E) with the top 
HADDOCK scores were used to represent the binding of HAV6 peptide to EC1. 
The EC1 residues that are involved in binding to cluster #1 are the T39, G40, D44, 
T45, F77, H79, A87, and P91 (Figure 2D) and cluster#3 are T39, G40, D44, T45, F77, 
and H79. This suggests that the binding pocket for HAV6 consists of residues T39, 
G40, D44, T45, F77, and H79 in the EC1 domain. The EC1 residues were affected by 
titration with HAV6 and showed good titration curves were used to estimate the Kd 
values of HAV6 (Figure 3D). Kd values of HAV6 estimated using residues T97, I4, 
V98, and V48 were 182, 225, 410, and 520 µM (Table 3).  
4.4 Discussion 
The goal of this study was to determine the binding properties of ADTc5, 
ADTc7, ADTc9, and HAV6 peptides to the EC1 domain of h-E-cadherin because 
ADT and HAV peptides have been shown to modulate the intercellular junctions 
the BBB to improve brain delivery of molecules in vivo. The hypothesis is that these 
peptides bind to the extracellular domain of E-cadherin to modulate cadherin-
cadherin interactions. Thus, the binding properties of ADT and HAV peptides to 
the EC1 domain of E-cadherin were evaluated because the X-ray and NMR 
structures of E-, N-, and C-cadherins have shown that the EC1 and EC2 domains 
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were involved in cadherin-cadherin interactions [9, 19, 25]. In the absence of X-ray 
data, a combination of NMR experimental data and molecular modeling methods 
(i.e., molecular dynamics and docking simulations) is a powerful tool to study 
ligand-receptor complexes for evaluating potential mechanisms of action of the 
ligand in biological systems [26, 27]. The EC1 domain used in this study contains a 
head EC1 domain with seven β-strand and two short α-helices and a tail region 
derived from a 28 amino acid sequence from the EC2 domain. In this study, the 
starting structure was derived from the X-ray structure h-E-cadherin with the 
extended tail region. Molecular dynamic simulations were carried out to the EC1 
starting structure and the final structure from MD simulations showed the tail 
domain swings into the head part to EC1 to form interactions [28]. 
The cyclic ADTc5 peptide has been shown to improve the brain delivery of 
marker molecules in vivo. Thus, this study was done to evaluate its binding 
properties to the EC1 domain of E-cadherin. Furthermore, ADTc7 and ADTc9 
peptides were designed as derivatives of ADTc5 in an attempt to understand role of 
the Val6 residue for its activity and design derivatives with better BBB modulatory 
activity. Mutation of Val6 residue was carried out because it was found previously 
to be important for peptide activity. In this study, the Val6 residue in ADTc5 was 
replaced with a negatively charged Glu6 in ADTc7 and an aromatic Tyr6 residue in 
ADTc9. Thus, the effects of these mutations were evaluated to the binding 
properties of ADTc7 and ADTc9 peptides to EC1. For ADTc5, seven out of eight 
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clusters from NMR-constrained molecular docking simulations bind to P6, S8, P10, 
T99, D103 and K105 residues (Figures 1A & 2A); the binding site for these clusters 
was consistent with the NMR data for chemical shift changes of the binding site 
residues. One out of eight clusters showed found ADTc5 bind to another a region 
around the Q23, N27, K30, Y36, and G58 residues. This region was different from 
the binding pocket of seven other clusters and was supported by the NMR data.  
The mutation of Val6 to Glu6 in ADTc7 peptide shifts the binding site of 
ADTc7 slightly to a binding pocket involving residues I4, N20, L21 and K105 
(Figures 1B and 2B); the CSP NMR data showed considerable CSP on the I4 and L21 
residues (Figure 2B). There was an overlap between the binding region of ADTc5 
and ADTc7. The docking experiments indicated that ADTc9 has a binding site 
defined by S9, E13, N20, L21, K105, P106, T125, and S126 residues (Figures 1C & 
2C). ADTc9 peptide had strong influence the L21 residue with considerable high 
CSP values upon peptide titration. There is binding region overlap between ADTc9 
and ADTc7 and slight overlap with ADTc5 binding site (Figure 4A).  
The differences in binding pockets of different ADT peptides on the EC1 
domain could influence in the binding affinity (i.e., Kd values). The mechanism 
activity of ADT peptides is proposed to be due to inhibition of domain swapping in 
the trans-dimer of two EC1 domains during cadherin-cadherin interaction. It has 
been shown that the domain swapping in C-cadherin domain is generated by 
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swapping W2 residues between the N-termini β-sheets of one EC1 domain to 
another EC1 domain. As in the C-cadherin, we also propose that the N-terminal 
residues of E-cadherin such W2, V3, I4, P5, P6 are involved in the domain swapping 
between two EC1 domains, in which the W2 side-chain interacts with the I24, Y36, 
S78, and A80 residues on the the hydrophobic pocket of another EC1 [9]. In order to 
perform domain swapping, the N-terminal β-sheet should be moved away from the 
current interactions within its EC1 domain (Figure 4C). However, the ADT peptide 
bind to the I4, P5 and P6 residues in this β-sheet; thus, this binding prevents the β-
sheet to move away from its current interaction for performing domain swapping.  
Another possible mechanism is that the binding of ADT peptides to the EC1 could 
prevent cis-dimer formation from the EC1 domain of one protein to the EC2-
domain of a neighboring protein from the same cell membranes. 
The blind docking HADDOCK experiments has been done as a control for 
NMR-constrain docking.   In the blind HADDOCK experiments, all three cyclic 
ADT peptides showed consistency with NMR-constrained docking results (Figure 
4B). The blind docking results showed cyclic ADT peptides clusters dock close to 
the “hot spot” region of EC1 (Figure 4B).   
The HAV6 peptide binds to the region of residues T39, T45, F77 and H79 on 
the EC1 domain (Figures 1D & 2D), which is a different binding site than those of 
ADT peptides (Figure 4A). The binding site of HAV6 was similar to the binding site 
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of cyclic cHAVc3 peptide (Cyclo(1,6)Ac-CSHAVC-NH2), which is a more potent 
peptide than HAV6 in modulating the BBB in vivo. The cyclic cHAVc3 peptide 
binds to the F77 and S78 residue on the EC1 domain [28].  
The affinities of cyclic ADT and HAV6 peptides to human EC1 domain were 
determined using CSP values of the residues of EC1 upon peptide titrations.  In 
general, the Kd values for ADT and HAV peptides fall in weak binding category 
(μM) to the EC1 domain (Table 3). The lowest estimated Kd values of ADTc5 (9 μM) 
and ADTc7 (10 μM) were lower than the lowest estimated Kd values of ADTc9 (190 
μM) (Table 3). In other words, ADTc7 and ADTc5 peptides have higher affinity to 
than ADTc9 peptide to the EC1 domain. The affinity of HAV6 peptide to the EC1 
domain (lowest Kd = 182 μM) was comparable to ADTc9 (190 µM). The cyclic 
cHAVc3 peptide has stronger binding affinity (Kd values = 5–20 µM) than linear 
HAV6 (Kd = 182 μM) [28] and these result is consistent with the in vivo data [18]. 
The activity of ADTc5 to modulate the BBB in vivo in Balb/c mice was 
higher than HAV6 peptide. With the same dose of ADTc5 and HAV6 (0.001 
mmol/kg), the ADTc5 has higher enhancement of the brain deposition of Gd-DTPA 
than that of HAV6 in the brain of Balb/c mice [17]. At the same dose (0.01 
mmol/kg), ADTc5 modulates the BBB for 2 h to allow the delivery of Gd-DTPA to 
the brain while the opening of the BBB is less than 1 h for HAV6 for delivering Gd-
DTPA to the brain [17]. The in vivo activity of cyclic cHAVc3 to deliver Gd-DTPA 
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to the brain was also better than linear HAV6 peptide. Cyclic cHAVc3 peptide 
activity to modulate the BBB was comparable to ADTc5 peptide and it modulates 
the BBB opening for 2 h time frame. Thus, the in vivo data were congruent with the 
EC1 binding data [17]. These results also indicate that the Val6 residue is an 
important residue in ADT peptide and replacing it can have impact on the binding 
affinity and binding site location on the EC1 domain.  
As shown in titration of the EC1 domain of with cyclic cHAVc3, the titration 
with ADT peptides (i.e., ADTc5, ADTc7, and ADTc9) and the linear HAV6 peptide 
also showed dramatic changes in the CSP in the D103 residue as well as other tail 
residues such as T125, G124, S126 (Figure 5). These changes presumably were due 
to conformational changes in the tail region upon peptide binding. The observed 
strong and medium CSP values upon titration with each peptide were shown in 
Figure 5. The molecular dynamic studies showed a dramatic change on the tail 
region from extended form away from the head EC1 domain to a folded form into 
the head EC1 to form globular structure. From our previous study, it is proposed 
that the D103 residue acts as a hinge for swinging the tail domain into the head EC1 
domain (Figure 5, see arrow). The D103 residue is also involved with clusters of 
calcium binding residues (i.e., PENE, DQND and LDRE) at the interface between 
EC1 and EC2; the presence of calcium ions at the interface between domains (e.g., 
between EC1–EC2, EC2–EC3) causes cadherin to convert from a globular structure 
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with folded EC domains to a rod-like structure where the domains form an 
extended rod of extracellular domain of cadherin [2, 10, 29]. 
In conclusion, ADT peptides (ADTc5, ADTc7, ADTc9) bind to a different 
region than HAV peptides (e.g., HAV6 and cHAVc3) on the EC1 domain. Mutation 
of Val6 residue in ADTc5 can influence the binding properties of ADT peptides. 
ADTc5 and ADTc7 have better binding properties than ADTc9 and HAV6 peptide, 
which is consistent with the in vivo studies. This study suggest that the NMR and 
molecular modeling methods can be used to improve the BBB modulatory activity 



















Table 1. Synthetic cadherin peptides sequences 
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Cluster#1   S9, P10, E13, K19, N20, L21, K105, P106, T125, G124, S126 
Cluster#2   S9, P10, E13, P16, N20, L21, W59, K105, F108, P106, T125, G124, S126 
Cluster#3   E13, P16, K19, N20, L21, K105, P106, T125, G124, Ser126 
Cluster#4   I4, P5, P6, I7, S8, P10, N20, L21, V22, W59, K105               
Cluster#5   P16, K19, N20, K105, P106, E107, F108, T125, S126, A132 
Cluster#6   P5, P6, I7, S8, P10, E13, N20, L21, D103, K105 
 
ADTc7 
Cluster#1   E13, K19, N20, L21, K105, P106, G124, S126, T125 
Cluster#2   I7, P10, E13, K19, N20, L21, K105, P106, T125, S126 
Cluster#3   G15, P18, K19, N20, L21, P106, Glu107, F108, T125, S126, A132 
Cluster#4   I4, P5, P6, I7, S8 L21K105, V122 
Cluster#5   I7, S8, E13, K19, N20, L21, W59 K105, P106, T125 
Cluster#6* T109, F113, K114, G115, S116, M128, V130 




Cluster#1    S8, S9, P10, T99, D100, Q101, N102, D103, K105,  
Cluster#2   P6, R68, T73, L95, T97, V98, T99, D100 
Cluster#3   P5, P6, I7, S8, P10, L21, T99 K105 
Cluster#4   I7, S8, S9, P10 T99, D100, Q101, N102, D103, N104, K105 
Cluster#5   P6, S8, S9, P10, T97, T99, D100, Q101, D103, K105 
Cluster#6*  Q23, K25, E56, G58, S26, N27, Y36, I24, D29, K30 
Cluster#7   W2, V3, P5, P6, I7, S8, L21, V22, Q23, W59 
Cluster#8   P6, S8, P10, T99D103, K105 
 
HAV6 
Cluster#1    T39, G40, D44, T45, F77, H79, A87, P91 
Cluster#2   T39, G40, D44, T45, F77, H79, A87, P91 
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Cluster#3   T39, G40, D44, T45, F77, H79 
Cluster#4   T39, G40, D44, T45, F77, H79, T75, N93. 
* Represent models that were dock differently from the other models for ADTc7 or 
ADTc5 peptides.  
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Table 3. Kd values in µM for each peptide for some 
EC1 residues 
Residues ADTc5 ADTc7 ADTc9 HAV6 
I4  10 255 225 
L21   190  
I24 20    
I53 10  403  
V48  16 500* 520 
G58 47    
T97  22  182 
V98  10 480 410 
G115 11 18  280 
E119 38   250 























 142  
Figure 1. The blue colors indicate where (A) ADTc9, (B) ATDc7, (C) ADTc5 or (D & 
E) HAV6 peptides dock to the EC1 domain. A potential binding site for (A) ADTc5 
on the EC1 domain as represented by clusters #5 and #8 with a common binding 
site around P6, S8, S9, T97, T99, P10, D100, Q101, D103, and K105 residues; (B) 
ADTc7 to the EC1 domain as represented by clusters #1 and #7 with a common 
binding site around E13, K19, N20, L21, K105, P106, G124, S126, and T125; (C) 
ADTc9 to the EC1 domain as represented by cluster #1 and cluster #2 with 
common binding site around S9, P10, E13, K19, N20, L21, K105, P106, G124, T125, 
and S126 residues; and (D & E) HAV6 to the EC1 domain as represented by cluster 
#1 and #3 with common binding site around T39, G40, D44, T45, F77, H79, A87, 
and P91 residues. 
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Figure 2. Shows the interaction of amino acids of each peptide with the residues on 
the EC1 domain for (A) ADTc5 cluster #5, (B) ATDc7 cluster #7, (C) ADTc9 cluster 
#1, and (D) HAV6 cluster #1. For simplicity only one cluster for each peptide was 
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Figure 3. Representatives of the best curve fitting of EC1 titration to estimate Kd 
values of binding for each peptide, including (A) ADTc5, (B) ADTc7, (C) ADTc9, 
and (D) HAV6. Titration curves were plotted as peptide-to-EC1 ratio vs. ΔF (ΔF = 
[(Δδ1H* (800.234 Hz/ppm))2 + (Δδ15N* (81.096 Hz/ppm))2]1/2). Kd values were 
estimated using simulated curve obtained by the following equation: Δobs = Δmax 
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Figure 4. (A) Comparison for favorable binding sites for ADT and HAV peptides on 
the EC1 domain: ADTc5 (blue), ADTc7 (gray), ADTc9 (magnet), and HAV6 peptide 
(yellow). Cyclic ADT peptides showed a binding site different from the HAV6 
peptide. (B) A common binding site for ADTc5, ADTc7, and ADTc9 on the EC1 
domain from a blind docking molecular docking experiment with HADDOCK. (C) 
Shows (upper) MD structure of E-cadherin domain with N-terminus β-sheet 
labeled in blue color and (lower) diagrams for domain swapping mechanism with 





























Cadherin-Cadherin Interaction  
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N-terminus β-sheet of EC1 domain labeled in blue color, too. In domain swapping, 
the β-sheet of EC1 domain (red-filled circle) should move to let its W2 binds to its 
hydrophobic pocket on the opposite EC1 domain (green-filled circle). ADT peptides 
bind to I4, P5 and P6 residues (Table 3). The hypothesis for ADT peptides activity is 
preventing the β-sheet movement from EC1 (red-filled circle) by binding to β-sheet 
I4, P5 and P6 residues. Thus, modulate the E-cadherin-E-cadherin interaction.  
 
Figure 5. The MD structure of EC1 domain showing residues with high (red) and 
low (green) ΔF values when titrated with (A) ADTc5, (B) ATDc7, (C) ADTc9, and 
(D) HAV6 peptides. The favorable binding site for each peptide showed more 
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conformational change. All peptides showed chemical shift changes in tail residues 
(black arrows) that may result from dynamic behavior of the EC1 tail when it 
titrated with the peptide and not from direct binding events. 
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5.1 Summary and Conclusions  
The objectives of this project were to modulate the blood-brain barrier (BBB) for 
brain deliver of molecules using cadherin peptides and to understand the mechanism of 
action of cadherin peptides. Although drug or diagnostic molecules might be available 
for treatment or diagnosis of brain diseases, the BBB acts as physical and enzymatical 
barriers to limit molecules from entering the brain with a sufficient and effective dose 
for pharmacological activity [1]. Thus, it makes the treatment of brain diseases 
challenging as well as contributing to high health care costs.  
The second chapter showed that cyclic HAVc3 peptide had better activity than 
linear HAV (HAV4) peptide in enhancing the delivery of marker molecules to the brain 
using in vitro and in vivo models of the BBB.  In the vitro model, cHAVc3 has shown 
better activity than HAV4 peptide in modulating the intercellular junctions of MDCK 
cell monolayers. In the vivo model, both peptides enhance the brain deposition of Gd-
DTPA and cyclic cHAVc3 peptide also has better BBB modulatory activity than HAV4 
peptide. The duration of BBB modulation in vivo for cHAVc3 was between 2–4 h while 
it was less than 1 h for HAV4 peptides. For a larger molecule, cHAVc3 and HAV4 
peptides can only delivery an IR-dye-800cw PEG (25 kDa) to the brain when they 
delivered together without time delay. The stability of cHAVc3 in rat plasma is about 
five-times (t1/2 = 12.9 h) higher compared to HAV4 peptide (t1/2 = 2.4 h). 
The hypothesis for the activity of cadherin peptides (HAV or ADT peptides) is 
that they bind to the EC1 domain to interrupt E-cadherin-to-E-cadherin interactions in 
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the intercellular junctions of the BBB. Using NMR and computational experiments, the 
binding sites and dissociation constants of cHAVc3 peptide were determined in 
Chapter 3. The NMR results showed that the cHAVc3 peptide binds to the EC1 domain 
of E-cadherin, providing support for the mechanism its BBB modulatory activity. The 
MD simulations data of EC1 showed that the tail part of the protein interacted with the 
head part of EC1 domain; this suggests that it mimicked the solution conformation of 
EC1. The tail part of the protein is sandwiched to the head of EC1 domain. The NMR 
titration data between cHAVc3 and EC1 showed that it bound to Y36, I38, F77, S78, and 
I94 residue on the EC1 domain and the Kd value of cHAVc3 peptide to EC1 domain was 
estimated to be around 0.5–7.0 X 10-5 M. 
Protein-protein interaction is important for biological cellular functions such as 
adhesion or signaling function. This interaction usually involves large surface areas 
between two proteins (e.g. domains) but the effectiveness and specificity of the binding 
often include a small area or “hot spot” [2]. In Chapter 4, binding sites of cyclic ADT 
and linear HAV peptides to EC1 domain were investigated and compared. The finding 
shows that cyclic ADT peptides (ADTc5, ADTc7, and ADTc9) have a common 
overlapping binding region on the EC1 domain while the HAV6 peptide has a different 
binding site on the EC1 domain. ADTc5 and ADTc7 have similar affinity to the EC1 
domain (Kd = 10 µM) and they have better affinity than ADTc9 and HAV6 peptides (Kd 
~ 190 µM).   
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5.2 Future Directions 
5.2.1 Optimization of Molecules being Delivery to the Brain 
As the delivery of molecules across the BBB remains to be a major challenge for 
drug delivery to the brain, the distribution of molecules in the brain tissues can pose 
another challenge. Although our studies showed the enhancement of marker molecules 
(such as Gd-DTPA and IR-dye-800cw PEG) to the brain models using cHAVc3 peptide, 
less information is known about the distribution of marker molecules in the brain. The 
extravascular space of the brain is narrow and tortuous and less molecules can traverse 
the extravascular space and reach the target site(s). In the future, we would like to 
investigate the bioavailability and brain distribution of delivered molecules upon 
enhanced delivery by cadherin peptides. One of the precise methods to evaluate 
molecules distribution in the brain tissues is by utilizing the brain slice method. This 
method keeps much of the brain cellular component integrity allowing us to accurately 
measure the distribution of molecules in the brain.  
5.2.2 Improving Specificity of HAV and ADT peptides 
The current clinical methods for the brain delivery are either by medical 
surgeries of the brain or a prolonged disruption of the BBB using hyperosmotic 
solutions [3]. Using peptides as BBB modulators to promote delivery to the brain has 
some advantages compared to the current hyperosmotic solution method. The BBB 
modulation by synthetic E-cadherin peptides (as BBB modulators) may have benefited 
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compared to hyperosmotic modifiers such as 25% mannitol.  The reason is that the 
chemistry of peptides allows one to do chemical modification on the peptides. For 
example, the specificity or potency of these peptides can be improved by mutation of 
residues flanking motif sequence (such as HAV) or making more rigid cyclic peptide 
using peptide bonds instead of disulfide bonds in cyclic HAV and ADT peptides. 
Another way to increase the specificity is by targeting a certain adhesion protein in the 
BBB such as the VE-cadherin [4]. Identifying the binding sites and dissociation 
constants for HAV and ADT peptides in EC1 domain or other domain of VE-cadherin 
may help to design molecules that bind specifically to VE-cadherin. This will increase 
targeting for endothelial cells and provide fewer tissues affected by synthetic E-
cadherin peptide modulators.  
  
5.2.3 Screening BBB modulators affinities 
NMR techniques can provide binding information at atomic level in solution 
state.  In addition, NMR methods can be used in high throughput (HP) drug design 
assays since it is a fast acquisition technique [5]. Thus, NMR can be used to explore the 
affinity peptide mutants from HAV or ADT peptides to enhance their potency and 
specificity to deliver drugs or molecules to the brain. 
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5.2.4 Brain Diseases: Treatment and Diagnosis  
As cyclic cHAVc3 peptide enhanced the delivery of molecules (i.e. small and 
large molecules) to the brain; this suggests cHAVc3 peptide is able to increase drug or 
diagnostic molecules, either small or large, to brain models. In the future, cHAVc3 will 
be used deliver large protein molecules, such as brain-derived neurotrophic factor 
(BDNF) and nerve growth factor (NGF), to the brain of neurodegenerative diseases such 
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